WO2024030535A2 - Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system - Google Patents
Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system Download PDFInfo
- Publication number
- WO2024030535A2 WO2024030535A2 PCT/US2023/029383 US2023029383W WO2024030535A2 WO 2024030535 A2 WO2024030535 A2 WO 2024030535A2 US 2023029383 W US2023029383 W US 2023029383W WO 2024030535 A2 WO2024030535 A2 WO 2024030535A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- alkyl
- group
- halo
- subject
- Prior art date
Links
- 208000002551 irritable bowel syndrome Diseases 0.000 title claims abstract description 57
- 230000003281 allosteric effect Effects 0.000 title abstract description 21
- 210000001428 peripheral nervous system Anatomy 0.000 title abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 158
- 102000004300 GABA-A Receptors Human genes 0.000 claims abstract description 49
- 108090000839 GABA-A Receptors Proteins 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 49
- 150000003839 salts Chemical class 0.000 claims abstract description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 38
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 22
- 208000002193 Pain Diseases 0.000 claims abstract description 20
- 210000000056 organ Anatomy 0.000 claims abstract description 18
- 208000004998 Abdominal Pain Diseases 0.000 claims abstract description 17
- 206010025476 Malabsorption Diseases 0.000 claims abstract description 17
- 208000004155 Malabsorption Syndromes Diseases 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 17
- 239000003833 bile salt Substances 0.000 claims abstract description 16
- 208000009935 visceral pain Diseases 0.000 claims abstract description 16
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 13
- 230000010243 gut motility Effects 0.000 claims abstract description 10
- 102100026189 Beta-galactosidase Human genes 0.000 claims abstract description 7
- 206010071200 Carbohydrate intolerance Diseases 0.000 claims abstract description 7
- 108010059881 Lactase Proteins 0.000 claims abstract description 7
- 108010005774 beta-Galactosidase Proteins 0.000 claims abstract description 7
- 229940116108 lactase Drugs 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 49
- -1 C1-6 halothioalkoxy Chemical group 0.000 claims description 46
- 125000005843 halogen group Chemical group 0.000 claims description 38
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 28
- 229910052757 nitrogen Inorganic materials 0.000 claims description 23
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 20
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 18
- 210000003169 central nervous system Anatomy 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 17
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
- 239000003937 drug carrier Substances 0.000 claims description 14
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 12
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 125000005309 thioalkoxy group Chemical group 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 210000000133 brain stem Anatomy 0.000 claims description 8
- 125000001246 bromo group Chemical group Br* 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 125000006413 ring segment Chemical group 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 4
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 44
- 201000010099 disease Diseases 0.000 abstract description 34
- 150000005829 chemical entities Chemical class 0.000 abstract description 20
- 230000008499 blood brain barrier function Effects 0.000 abstract description 18
- 210000001218 blood-brain barrier Anatomy 0.000 abstract description 18
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 10
- 208000026935 allergic disease Diseases 0.000 abstract description 10
- 208000035475 disorder Diseases 0.000 abstract description 10
- 230000009610 hypersensitivity Effects 0.000 abstract description 10
- 230000009885 systemic effect Effects 0.000 abstract description 9
- 208000019901 Anxiety disease Diseases 0.000 abstract description 8
- 208000000668 Chronic Pancreatitis Diseases 0.000 abstract description 8
- 206010033649 Pancreatitis chronic Diseases 0.000 abstract description 8
- 230000036506 anxiety Effects 0.000 abstract description 8
- 208000011231 Crohn disease Diseases 0.000 abstract description 7
- 208000005171 Dysmenorrhea Diseases 0.000 abstract description 7
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract description 7
- 208000005615 Interstitial Cystitis Diseases 0.000 abstract description 7
- 150000001204 N-oxides Chemical class 0.000 abstract description 7
- 230000006735 deficit Effects 0.000 abstract description 7
- 201000006549 dyspepsia Diseases 0.000 abstract description 7
- 208000001914 Fragile X syndrome Diseases 0.000 abstract description 6
- 208000033180 Monosomy 22q13.3 Diseases 0.000 abstract description 6
- 208000001294 Nociceptive Pain Diseases 0.000 abstract description 6
- 201000006880 Phelan-McDermid syndrome Diseases 0.000 abstract description 6
- 208000006289 Rett Syndrome Diseases 0.000 abstract description 6
- 208000006673 asthma Diseases 0.000 abstract description 6
- 208000029560 autism spectrum disease Diseases 0.000 abstract description 6
- 230000009286 beneficial effect Effects 0.000 abstract description 6
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 6
- 230000004064 dysfunction Effects 0.000 abstract description 6
- 230000001404 mediated effect Effects 0.000 abstract description 5
- 230000001537 neural effect Effects 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 description 45
- 239000000243 solution Substances 0.000 description 41
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 210000004556 brain Anatomy 0.000 description 21
- 229940126027 positive allosteric modulator Drugs 0.000 description 19
- 208000024891 symptom Diseases 0.000 description 19
- 239000007787 solid Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 239000000969 carrier Substances 0.000 description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 8
- 206010010774 Constipation Diseases 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000003599 detergent Substances 0.000 description 6
- 230000008587 neuronal excitability Effects 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 229940049706 benzodiazepine Drugs 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 239000008121 dextrose Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 210000000105 enteric nervous system Anatomy 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 239000006186 oral dosage form Substances 0.000 description 5
- 235000013772 propylene glycol Nutrition 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 150000005840 aryl radicals Chemical class 0.000 description 4
- 150000001557 benzodiazepines Chemical class 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000004899 motility Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 206010039897 Sedation Diseases 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940047766 co-trimoxazole Drugs 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000001839 endoscopy Methods 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthene Chemical group C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 230000008533 pain sensitivity Effects 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000036280 sedation Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229940083542 sodium Drugs 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- DOQZPNMRQNJIIQ-UHFFFAOYSA-N (2-azido-5-chlorophenyl)-(2-fluorophenyl)methanone Chemical compound FC1=CC=CC=C1C(=O)C1=CC(Cl)=CC=C1N=[N+]=[N-] DOQZPNMRQNJIIQ-UHFFFAOYSA-N 0.000 description 2
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000589876 Campylobacter Species 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 2
- 102000005915 GABA Receptors Human genes 0.000 description 2
- 108010005551 GABA Receptors Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical group C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
- 229960004099 azithromycin Drugs 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical group C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- DGQLVPJVXFOQEV-JNVSTXMASA-N carminic acid Chemical compound OC1=C2C(=O)C=3C(C)=C(C(O)=O)C(O)=CC=3C(=O)C2=C(O)C(O)=C1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DGQLVPJVXFOQEV-JNVSTXMASA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical group C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 238000002052 colonoscopy Methods 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 210000004921 distal colon Anatomy 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 229960004667 ethyl cellulose Drugs 0.000 description 2
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009541 flexible sigmoidoscopy Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 210000001222 gaba-ergic neuron Anatomy 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229960003040 rifaximin Drugs 0.000 description 2
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- GTGMXPIQRQSORU-UHFFFAOYSA-N (2-amino-5-chlorophenyl)-(2-fluorophenyl)methanone Chemical compound NC1=CC=C(Cl)C=C1C(=O)C1=CC=CC=C1F GTGMXPIQRQSORU-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- YQVZREHUWCCHHX-UHFFFAOYSA-N (4-chlorophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=C(Cl)C=C1 YQVZREHUWCCHHX-UHFFFAOYSA-N 0.000 description 1
- RUJBDQSFYCKFAA-HNNXBMFYSA-N (5r)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine Chemical compound C1([C@H](C(=NN=2)C)CC)=CC(OC)=C(OC)C=C1C=2C1=CC=C(OC)C(OC)=C1 RUJBDQSFYCKFAA-HNNXBMFYSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- JCMLWGQJPSGGEI-HZAMXZRMSA-N 2-[[2-[(2s)-2-[(3r,5s,7r,8r,9s,10s,12s,13s,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]propyl]selanylacetyl]amino]ethanesulfonic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](C[Se]CC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JCMLWGQJPSGGEI-HZAMXZRMSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 1
- 239000003185 4 aminobutyric acid B receptor stimulating agent Substances 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- XBHBWNFJWIASRO-UHFFFAOYSA-N 6-fluoro-1-(4-fluorophenyl)-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1=CC=C(F)C=C1 XBHBWNFJWIASRO-UHFFFAOYSA-N 0.000 description 1
- IOIZWEJGGCZDOL-RQDYSCIWSA-N 7alpha-hydroxycholest-4-en-3-one Chemical compound C([C@H]1O)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 IOIZWEJGGCZDOL-RQDYSCIWSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 description 1
- QHKJMJWBYCESIM-UHFFFAOYSA-N CCOC(C1=C(CBr)N(C(C=CC(Cl)=C2)=C2C(C(C=CC=C2)=C2F)=O)N=C1)=O Chemical compound CCOC(C1=C(CBr)N(C(C=CC(Cl)=C2)=C2C(C(C=CC=C2)=C2F)=O)N=C1)=O QHKJMJWBYCESIM-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- UDHXJZHVNHGCEC-UHFFFAOYSA-N Chlorophacinone Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)C(=O)C1C(=O)C2=CC=CC=C2C1=O UDHXJZHVNHGCEC-UHFFFAOYSA-N 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 241000179197 Cyclospora Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010023804 Large intestine perforation Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241000607000 Plesiomonas Species 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 206010036783 Proctitis ulcerative Diseases 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000031074 Reinjury Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- RUJBDQSFYCKFAA-UHFFFAOYSA-N Tofisopam Chemical compound N=1N=C(C)C(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=C(OC)C(OC)=C1 RUJBDQSFYCKFAA-UHFFFAOYSA-N 0.000 description 1
- 208000037175 Travel-Related Illness Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- SLGBZMMZGDRARJ-UHFFFAOYSA-N Triphenylene Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC=C3C2=C1 SLGBZMMZGDRARJ-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 206010047400 Vibrio infections Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- JDPAVWAQGBGGHD-UHFFFAOYSA-N aceanthrylene Chemical group C1=CC=C2C(C=CC3=CC=C4)=C3C4=CC2=C1 JDPAVWAQGBGGHD-UHFFFAOYSA-N 0.000 description 1
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- SQFPKRNUGBRTAR-UHFFFAOYSA-N acephenanthrylene Chemical group C1=CC(C=C2)=C3C2=CC2=CC=CC=C2C3=C1 SQFPKRNUGBRTAR-UHFFFAOYSA-N 0.000 description 1
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Chemical group C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000003766 afferent neuron Anatomy 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FLZQKRKHLSUHOR-UHFFFAOYSA-N alosetron Chemical compound CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 description 1
- 229960003550 alosetron Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- KNNXFYIMEYKHBZ-UHFFFAOYSA-N as-indacene Chemical group C1=CC2=CC=CC2=C2C=CC=C21 KNNXFYIMEYKHBZ-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 229940098166 bactrim Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005870 benzindolyl group Chemical group 0.000 description 1
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000005878 benzonaphthofuranyl group Chemical group 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000001511 capsicum annuum Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229950009781 dextofisopam Drugs 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- 125000005509 dibenzothiophenyl group Chemical group 0.000 description 1
- PREAJPIKNPDDON-APAIHEESSA-N dideuterio-[dichloro(deuterio)methyl]-lambda3-chlorane Chemical compound C(Cl([2H])[2H])(Cl)(Cl)[2H] PREAJPIKNPDDON-APAIHEESSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- LGTLXDJOAJDFLR-UHFFFAOYSA-N diethyl chlorophosphate Chemical compound CCOP(Cl)(=O)OCC LGTLXDJOAJDFLR-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002567 electromyography Methods 0.000 description 1
- QFNHIDANIVGXPE-FNZWTVRRSA-N eluxadoline Chemical compound C1=C(C(O)=O)C(OC)=CC=C1CN(C(=O)[C@@H](N)CC=1C(=CC(=CC=1C)C(N)=O)C)[C@@H](C)C1=NC(C=2C=CC=CC=2)=CN1 QFNHIDANIVGXPE-FNZWTVRRSA-N 0.000 description 1
- 229960002658 eluxadoline Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 210000002322 enterochromaffin cell Anatomy 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- FPULFENIJDPZBX-UHFFFAOYSA-N ethyl 2-isocyanoacetate Chemical compound CCOC(=O)C[N+]#[C-] FPULFENIJDPZBX-UHFFFAOYSA-N 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical group C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000012909 foetal bovine serum Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 244000078673 foodborn pathogen Species 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000003371 gabaergic effect Effects 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013761 grape skin extract Nutrition 0.000 description 1
- 230000007149 gut brain axis pathway Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 229950007954 ibafloxacin Drugs 0.000 description 1
- DXKRGNXUIRKXNR-UHFFFAOYSA-N ibafloxacin Chemical compound C1CC(C)N2C=C(C(O)=O)C(=O)C3=C2C1=C(C)C(F)=C3 DXKRGNXUIRKXNR-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- KXGCNMMJRFDFNR-WDRJZQOASA-N linaclotide Chemical compound C([C@H](NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@H]3CSSC[C@H](N)C(=O)N[C@H](C(N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N2)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC3=O)C(=O)N[C@H](C(NCC(=O)N1)=O)[C@H](O)C)C(O)=O)C1=CC=C(O)C=C1 KXGCNMMJRFDFNR-WDRJZQOASA-N 0.000 description 1
- 229960000812 linaclotide Drugs 0.000 description 1
- 108010024409 linaclotide Proteins 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000011475 lollipops Nutrition 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- WGFOBBZOWHGYQH-MXHNKVEKSA-N lubiprostone Chemical compound O1[C@](C(F)(F)CCCC)(O)CC[C@@H]2[C@@H](CCCCCCC(O)=O)C(=O)C[C@H]21 WGFOBBZOWHGYQH-MXHNKVEKSA-N 0.000 description 1
- 229960000345 lubiprostone Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- SYPLUFBJMSFMTN-UHFFFAOYSA-N methyl 4-hydroxybut-2-ynoate Chemical compound COC(=O)C#CCO SYPLUFBJMSFMTN-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000897 modulatory effect Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000003183 myoelectrical effect Effects 0.000 description 1
- BGTBRDJUHRMBQB-UHFFFAOYSA-N n,n-dimethylmethanamine;n,n-dipropylpropan-1-amine Chemical compound CN(C)C.CCCN(CCC)CCC BGTBRDJUHRMBQB-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 108091008700 nociceptors Proteins 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Chemical group C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- PBDBXAQKXCXZCJ-UHFFFAOYSA-L palladium(2+);2,2,2-trifluoroacetate Chemical compound [Pd+2].[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F PBDBXAQKXCXZCJ-UHFFFAOYSA-L 0.000 description 1
- 208000014965 pancolitis Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- NQFOGDIWKQWFMN-UHFFFAOYSA-N phenalene Chemical compound C1=CC([CH]C=C2)=C3C2=CC=CC3=C1 NQFOGDIWKQWFMN-UHFFFAOYSA-N 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- DIJNSQQKNIVDPV-UHFFFAOYSA-N pleiadene Chemical compound C1=C2[CH]C=CC=C2C=C2C=CC=C3[C]2C1=CC=C3 DIJNSQQKNIVDPV-UHFFFAOYSA-N 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- LZLXHGFNOWILIY-APPDUMDISA-N pradofloxacin Chemical compound C12=C(C#N)C(N3C[C@H]4NCCC[C@H]4C3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 LZLXHGFNOWILIY-APPDUMDISA-N 0.000 description 1
- 229960001248 pradofloxacin Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 206010036784 proctocolitis Diseases 0.000 description 1
- 208000017048 proctosigmoiditis Diseases 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229960003889 rosoxacin Drugs 0.000 description 1
- XBPZXDSZHPDXQU-UHFFFAOYSA-N rosoxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC=C1C1=CC=NC=C1 XBPZXDSZHPDXQU-UHFFFAOYSA-N 0.000 description 1
- 229950007734 sarafloxacin Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000002563 stool test Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 description 1
- 229960002876 tegaserod Drugs 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 229960002501 tofisopam Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000005580 triphenylene group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof, or an N-oxide thereof), which are positive allosteric modulators of one or more GABA-A receptors, e.g., which are peripherally restricted, positive allosteric modulators of one or more GABA-A receptors; e.g., which are positive allosteric modulators of one or more GABA-A receptors and which selectively target the peripheral nervous system and organs of the body, and which do not substantially pass through the blood-brain barrier.
- chemical entities e.g., a compound or a pharmaceutically acceptable salt thereof, or an N-oxide thereof
- Said compounds are useful e.g., for the treatment of systemic diseases of the body, e.g., diseases in which modulation of one or more peripherally restricted GABA-A receptors is beneficial (e.g., diseases or disorders which are mediated by GABA-A neuronal activity, such as, visceral pain, gut motility, irritable bowel syndrome, functional abdominal pain, functional idiopathic diarrhea, inflammatory bowel diseases (e.g., Crohn’s disease), drug induced pain, bile salt malabsorption, lactase or other carbohydrate intolerance, interstitial cystitis, chronic pancreatitis, functional dyspepsia, dysmenorrhea, tactile hypersensitivity, tactile dysfunction, somatic pain, asthma, diabetes, anxiety, social impairment, autism spectrum disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome).
- diseases or disorders which are mediated by GABA-A neuronal activity such as, visceral pain, gut motility, irritable
- the chemical entities described herein are useful, e.g., for the treatment of diseases, such as irritable bowel syndrome.
- This disclosure also features pharmaceutical compositions containing the chemical entities described herein as well as methods for the treatment of systemic diseases of the body (e.g., irritable bowel syndrome), which include administering an effective amount of a chemical entity described herein.
- IBS Irritable bowel syndrome
- IBS-D diarrhea predominant
- IBS-C constipation predominant
- IBS-M mixed or alternating between diarrhea and constipation
- GABA Gamma Aminobutyric Acid
- CNS central nervous system
- GABA-ergic neurons are also abundant in the enteric nervous system and both GABA-A (inotropic) and GABA-B (metabotropic) receptors are present in the gut, mediating distinct functional effects. 5 ' 13 GABA- B receptor agonists have been investigated for treatment of IBS. 14
- GABA-A receptor positive allosteric modulators have heretofore been concerned with CNS conditions like anxiety, insomnia, and epilepsy not IBS.
- WO 2015/200766 discloses positive allosteric modulators of one or more GABA- A receptors, which selectively target the peripheral nervous system and organs of the body, and which do not substantially pass through the blood-brain barrier.
- WO 2020/198275 discloses peripherally-restricted benzodiazepines with reduced blood brain barrier permeability.
- This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof, or an N-oxide thereof), which are positive allosteric modulators of one or more GABA-A receptors, e.g., which are peripherally restricted, positive allosteric modulators of one or more GABA-A receptors; e.g., which are positive allosteric modulators of one or more GABA-A receptors and which selectively target the peripheral nervous system and organs of the body, and which do not substantially pass through the blood-brain barrier.
- chemical entities e.g., a compound or a pharmaceutically acceptable salt thereof, or an N-oxide thereof
- Said compounds are useful e.g., for the treatment of systemic diseases of the body, e.g., diseases in which modulation of one or more peripherally restricted GABA-A receptors is beneficial (e.g., diseases or disorders which are mediated by GABA-A neuronal activity, such as, visceral pain, gut motility, irritable bowel syndrome (e.g., Crohn’s disease), functional abdominal pain, functional idiopathic diarrhea, inflammatory bowel diseases, drug induced pain, bile salt malabsorption, lactase or other carbohydrate intolerance, interstitial cystitis, chronic pancreatitis, functional dyspepsia, dysmenorrhea, tactile hypersensitivity, tactile dysfunction, somatic pain, asthma, diabetes, anxiety, social impairment, autism spectrum disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome).
- diseases or disorders which are mediated by GABA-A neuronal activity such as, visceral pain, gut motility, irritable
- the chemical entities described herein are useful, e.g., for the treatment of diseases, such as irritable bowel syndrome.
- This disclosure also features pharmaceutical compositions containing the chemical entities described herein as well as methods for the treatment of systemic diseases of the body (e.g., irritable bowel syndrome), which include administering an effective amount of a chemical entity described herein.
- this disclosure provides compounds which are GABA-A receptor positive allosteric modulators that are peripherally-restricted to the GABAergic neurons of the body that are present outside of the brain and central nervous system.
- R la , R lb , R lc , R ld , m, R 2 , A 1 , A 2 , X , R 4 , R 5 , and Z can be defined anywhere herein.
- compositions comprising a compound of Formula (I) as described anywhere herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- this disclosure provides methods and uses of the compounds described herein for positive modulation of GABA-A receptors in tissues and organs outside the brain.
- said methods can be carried out in vitro.
- said methods can be carried out in vivo.
- provided herein is a method of positively modulating GABA-A receptors in tissues and organs outside the brain and central nervous system in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described anywhere herein.
- this disclosure provides methods for treating or preventing (e.g., treating) visceral pain and modulating gut motility, such as in irritable bowel syndrome (e.g., Crohn’s disease), in a subject comprising the administration of a therapeutically effective amount of a peripherally-restricted GABA-A receptor positive allosteric modulator described.
- a method of treating or preventing (e.g., treating) visceral pain in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described anywhere herein.
- provided herein is a method of modulating gut motility in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described anywhere herein.
- this disclosure provides a method of treating irritable bowel syndrome in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described anywhere herein.
- this disclosure provides a method of treating functional abdominal pain, functional idiopathic diarrhea, inflammatory bowel diseases, drug induced pain, bile salt malabsorption, lactase or other carbohydrate intolerance, interstitial cystitis, chronic pancreatitis, functional dyspepsia, dysmenorrhea, tactile hypersensitivity, tactile dysfunction, somatic pain, asthma, diabetes, anxiety, social impairment, autism spectrum disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described anywhere herein.
- this disclosure provides methods for suppressing neuronal excitability in tissues and organs outside of the brain and central nervous system, the method comprising administering to a subject in need of such suppressing a therapeutically effective amount of a chemical entity disclosed anywhere herein (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof, or an N-oxide thereof).
- a chemical entity disclosed anywhere herein (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof, or an N-oxide thereof).
- compositions comprising compounds for positive modulation of GABA-A receptors in tissues and organs outside the brain as disclosed herein, and at least one additional therapeutic agent.
- compositions comprising compounds as disclosed herein, and at least one additional therapeutic agent for positive modulation of GABA-A receptors in tissues and organs outside the brain.
- This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof, or an N-oxide thereof), which are positive allosteric modulators of one or more GABA-A receptors, e.g., which are peripherally restricted, positive allosteric modulators of one or more GABA-A receptors; e.g., which are positive allosteric modulators of one or more GABA-A receptors and which selectively target the peripheral nervous system and organs of the body, and which do not substantially pass through the blood-brain barrier.
- chemical entities e.g., a compound or a pharmaceutically acceptable salt thereof, or an N-oxide thereof
- Said compounds are useful e.g., for the treatment of systemic diseases of the body, e.g., diseases in which modulation of one or more peripherally restricted GABA-A receptors is beneficial (e.g., diseases or disorders which are mediated by GABA-A neuronal activity, such as, visceral pain, gut motility, irritable bowel syndrome, functional abdominal pain, functional idiopathic diarrhea, inflammatory bowel diseases (e.g., Crohn’s disease), drug induced pain, bile salt malabsorption, lactase or other carbohydrate intolerance, interstitial cystitis, chronic pancreatitis, functional dyspepsia, dysmenorrhea, tactile hypersensitivity, tactile dysfunction, somatic pain, asthma, diabetes, anxiety, social impairment, autism spectrum disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome).
- diseases or disorders which are mediated by GABA-A neuronal activity such as, visceral pain, gut motility, irritable
- the chemical entities described herein are useful, e.g., for the treatment of diseases, such as irritable bowel syndrome.
- This disclosure also features pharmaceutical compositions containing the chemical entities described herein as well as methods for the treatment of systemic diseases of the body (e.g., irritable bowel syndrome), which include administering an effective amount of a chemical entity described herein.
- this disclosure provides methods for treatment of visceral pain and modulating gut motility in a subject, such as that caused by IBS, by positively modulating the GABA-A receptor in the enteric nervous system without the usual CNS side effects of GABA modulation is provided. It is contemplated that the methods described herein are effective in treating visceral pain caused by other ailments, not only IBS.
- non-IBS related ailments which can be treated by the inventive methods, include functional abdominal pain, functional idiopathic diarrhea, inflammatory bowel diseases such as Crohn’s disease, drug induced pain, bile salt malabsorption, lactase or other carbohydrate intolerance, interstitial cystitis, chronic pancreatitis, functional dyspepsia, dysmenorrhea, tactile hypersensitivity, somatic pain, asthma, and diabetes.
- this disclosure provides methods for the treatment of tactile dysfunction, anxiety, or social impairment in a subject in need thereof, the method comprising administering to the subject a chemical entity disclosed anywhere herein (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof, or an N-oxide thereof).
- a chemical entity disclosed anywhere herein e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof, or an N-oxide thereof.
- the subject is diagnosed with Autism Spectrum Disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome.
- this disclosure provides methods for suppressing neuronal excitability in tissues and organs outside of the brain and central nervous system, the method comprising administering to a subject in need of such suppressing a therapeutically effective amount of a peripherally-restricted GABA-A receptor positive allosteric modulator, wherein the peripherally-restricted GABA-A receptor positive allosteric modulator is a chemical entity disclosed anywhere herein (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof, or an N-oxide thereof).
- neuronal excitability is GABAergic neuronal excitability in tissues and organs outside of the brain and central nervous system.
- suppressing neuronal excitability in tissues and organs outside of the brain and central nervous system comprises positively modulating GABA-A receptors in tissues and organs outside the brain and central nervous system.
- the peripherally- restricted GABA-A receptor positive allosteric modulator does not substantially cross an intact blood brain barrier of the subject. In some embodiments, less than 50% (e.g., less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, less than 1%, less than 0.5%, or less than 0.1%) of the peripherally-restricted GABA-A receptor positive allosteric modulator crosses an intact blood brain barrier of the subject.
- less than 5% of the peripherally-restricted GABA-A receptor positive allosteric modulator crosses an intact blood brain barrier of the subject. In certain embodiments, less than 1% (e.g., less than 0.5% or less than 0.1%) of the peripherally-restricted GABA-A receptor positive allosteric modulator crosses an intact blood brain barrier of the subject. In some embodiments, the ratio of a concentration of the peripherally -restricted GABA-A receptor positive allosteric modulator in the brain to a concentration of the peripherally-restricted GABA-A receptor positive allosteric modulator in the circulating plasma is about 1 :5.
- the ratio of a concentration of the peripherally -restricted GABA-A receptor positive allosteric modulator in the brain to a concentration of the peripherally-restricted GABA-A receptor positive allosteric modulator in the circulating plasma is about 1 :10. In some embodiments, the average concentration of the peripherally -restricted GABA-A receptor positive allosteric modulator in the brain is less than 62.5 nM. In some embodiments, the peripherally-restricted GABA-A receptor positive allosteric modulator binds to the GABA-A receptor with a Ki of less than 500 nM.
- the peripherally-restricted GABA-A receptor positive allosteric modulator is a pharmaceutically acceptable salt of the compound of Formula (I) (e.g., a pharmaceutically acceptable salt of a compound delineated in Table Cl).
- the peripherally-restricted GABA-A receptor positive allosteric modulator is a compound of Formula (I).
- the peripherally-restricted GABA-A receptor positive allosteric modulator can be a compound delineated in Table Cl.
- the method further comprises administering the peripherally-restricted GABA-A receptor positive allosteric modulator as a pharmaceutical composition comprising the peripherally-restricted GABA-A receptor positive allosteric modulator and a pharmaceutically acceptable carrier. In some embodiments, the method further comprises administering at least one additional therapeutic agent. In some embodiments, the method further comprises administering at least one additional therapeutic agent for positive modulation of GABA-A receptors in tissues and organs outside the brain.
- GABA-A receptor positive allosteric modulators used in this disclosure, are restricted from the CNS so they do not produce unwanted side effects such as sedation yet still exert beneficial pharmacological effects on the enteric nervous system.
- BBB blood brain barrier
- This disclosure provides, inter alia, chemical compounds according to Formula (I), and pharmaceutically acceptable salts, solvates, and stereoisomers thereof, or any prodrug equivalents (such as esters) thereof, wherein the compound contains a functional group that reduces blood-brain barrier permeability, as shown below.
- this disclosure features compounds of Formula (I):
- each of A 1 and A 2 is independently selected from the group consisting of N and CR 3 , provided that one of A 1 and A 2 is N;
- X A and X B are independently O, S, N(H), or N(CI-3 alkyl);
- R x is selected from the group consisting of: H, Ci-6 alkyl, -OH, and -NR 6 R 7 ;
- Y is selected from the group consisting of:
- Y 2 is C2-6 alkylene
- Y 4 is H or C1-6 alkyl
- R 3 is selected from the group consisting of:
- R 4 and R 5 are independently selected from the group consisting of: H, C1-6 alkyl, -OH, and -NR 6 R 7 ; or
- Z is a lone pair of electrons
- the compound is other than the compounds disclosed in WO2018035246.
- one of A 1 and A 2 is N, and the other of A 1 and A 2 is CR 3 .
- a 1 is N, and A 2 is CR 3 .
- a 2 is N, and A 1 is CR 3 .
- R la , R lb , R lc , and R ld is an independently selected substituent other than H.
- a 1 and A 2 are both N.
- R la , R lb , R lc , and R ld is an independently selected substituent other than H.
- one of R la , R lb , R lc , and R ld is selected from the group consisting of: C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 alkoxy, C1-6 haloalkoxy, C1-6 thioalkoxy, C1-6 halothioalkoxy, and C3-6 cycloalkyl; and the other three of R la , R lb , R lc , and R ld are H.
- one of R la , R lb , R lc , and R ld is C1-6 alkyl; and the other three of R la , R lb , R lc , and R ld are H.
- one of R la , R lb , R lc , and R ld is halo; and the other three of R la , R lb , R lc , and R ld are H.
- R lc is selected from the group consisting of: C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 thioalkoxy, C1-6 halothioalkoxy, and C3-6 cycloalkyl.
- n is 1 or 2. In certain embodiments, m is 1.
- n 0 or 1. In certain embodiments, ml is 1.
- each R 2 is independently selected from the group consisting of: halo, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, NO2, cyano, C1-6 alkoxy, C1-6 haloalkoxy, SO2(Ci-6 alkyl), and C3-6 cycloalkyl.
- each R 2 is independently selected from the group consisting of: halo, C1-6 alkyl, C1-6 haloalkyl, cyano, C1-6 alkoxy, and C1-6 haloalkoxy. [0046] In certain embodiments, each R 2 is an independently selected halo, optionally -F, -Cl, or -Br.
- each of R 4 and R 5 is H.
- one of R 4 and R 5 is Ci-6 alkyl (e.g., CH3); and the other of R 4 and R 5 is H.
- X is -CO2H or -CH(R X )CO2H.
- X is -CO2H.
- X is -C(O)Y or -CH(R X )C(O)Y.
- X is -C(O)Y.
- Y is -NR 6 R 7 , such as wherein Y is NH2, NH(CI-3 alkyl), or N(CI-3 alkyl)2.
- Y is -NR 8 -Y 2 -Y 3 .
- Y is -N(H)-Y 2 -Y 3 .
- Y 2 is straight-chain C2-4 alkylene, such as -CH2CH2- or - CH2CH2CH2-.
- Y 3 is -NR 9 S(O)2NR 9 R 10 , such as -NHS(O)2NH2.
- R 3 is H.
- R 3 is halo, such as -Cl or -Br.
- R 3 is C1-6 alkyl or C1-6 haloalkyl, such as wherein R 3 is Ci-
- alkyl such as methyl
- R la , R lb , R lc , and R ld is C1-6 alkyl, cyano, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 thioalkoxy, C1-6 halothioalkoxy, or halo (e.g., Br or -Cl); optionally R lc is C1-6 alkyl or halo (e.g., Br or -Cl);
- m is 1 or 2 (e.g., 1);
- each R 2 is an independently selected halo, such as -F, -Cl, or -Br;
- a 1 is N, and A 2 is CR 3 ; or A 2 is N, and A 1 is CR 3 ; or A 1 is N, and A 2 is N.
- R la , R lb , R lc , and R ld is Ci-6 alkyl or halo (e.g., Br or -Cl); optionally R lc is Ci-6 alkyl or halo (e.g., Br or -Cl);
- m is 1 or 2 (e.g., 1);
- each R 2 is an independently selected halo, such as -F, -Cl, or -Br;
- a 1 is N, and A 2 is CR 3 ; or A 2 is N, and A 1 is CR 3 ; or A 1 is N, and A 2 is N.
- one of R la , R lb , R lc , and R ld is Ci-6 alkyl, optionally R lc is Ci-6 alkyl.
- one of R la , R lb , R lc , and R ld is halo (e.g., Br or -Cl), optionally R lc is halo (e.g., Br or -Cl).
- m is 1.
- R 4 and R 5 are each H.
- one of R 4 and R 5 is Ci-6 alkyl (e.g., CH3); and the other of
- R 4 and R 5 is H.
- X is -CO2H or -CH(R X )CO2H.
- X is -CO2H.
- Z is a lone pair of electrons.
- Z is ' e
- the compound is selected from the group consisting of the compounds in Table Cl, or a pharmaceutically acceptable salt thereof.
- this disclosure provides pharmaceutical compositions comprising the compounds of Formula (I), as described herein, and a pharmaceutically acceptable carrier.
- a salt e.g., a pharmaceutically acceptable salt of the Formula (I) compounds described herein.
- peripheral nervous system generally refers to a chemical entity (e.g., a compound or a pharmaceutically acceptable thereof) that does not substantially cross an intact blood brain barrier of a subject.
- a chemical entity e.g., a compound or a pharmaceutically acceptable thereof
- the term also encompasses compounds that may cross an intact blood brain barrier, but upon administration is rapidly metabolized to a form that does not substantially cross an intact blood brain barrier of the subject.
- a compound may be considered “peripherally restricted” if, upon administration to a subject, less than 50%, less than 45%, less than 40%, less than 35%, less than 30%, less than 25%, less than 20%, less than 15%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.1% of the compound crosses an intact blood brain barrier of the subject.
- the term “peripherally restricted can mean that the concentration of a compound in the brain compared to the concentration in the circulating plasma (braimplasma) ratio of about 1 :5 or greater (e.g., about 1 : 10 or greater).
- the braimplasma ratio is determined by measuring the ratio of a compound in mice or rats.
- an effective amount or “a therapeutically effective amount” refers to the amount of a compound that is sufficient to affect the intended application, including but not limited to disease treatment, as defined below.
- the therapeutically effective amount may vary depending upon the intended treatment application (in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
- the term also applies to a dose that will induce a particular response in target cells. The specific dose will vary depending on the particular compounds chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried.
- positive modulation or “positive allosteric modulation” and all words stemming therefrom, refer to compounds that bind to an allosteric site on a receptor complex and affect it in a positive manner. Affecting a receptor in a positive manner typically means causing increased efficiency of the main receptor site. Increased receptor efficiency can mean potentially inducing a receptor to undergo a conformational change, or where the channel opens more frequently or for longer periods of time when an agonist binds to the receptor.
- visceral pain refers to pain that results from the activation of nociceptors of the thoracic, pelvic, or abdominal organs.
- problems with organs for example but not limited to, the stomach, kidney, gallbladder, urinary bladder, pancreas, and intestines, can lead to visceral pain.
- Such problems can include distension, perforation, inflammation, impaction, and constipation.
- the visceral pain can be diffuse, vague, dull, deep, squeezing, pressure-like, and difficult to localize.
- the visceral pain may be accompanied by symptoms such as nausea, vomiting, sweating, and changes in blood pressure, heart rate, and temperature. Visceral pain can often be experienced, or “referred” to different sites of the body.
- visceral pain can be associated with functional dyspepsia, interstitial cystitis, chronic pancreatitis, or dysmenorrhea.
- gut motility refers to stretching and contractions of the muscles of the gastrointestinal tract. Peristaltic movement is the cyclical relaxation of circular smooth muscles, followed by their longitudinal contraction. Gut motility can be impaired, which can lead to abnormal contractions, including spasms and paralysis.
- IBS irritable bowel syndrome
- Symptoms of IBS can include, e.g., abdominal pain, abdominal discomfort, constipation, diarrhea, mucus in the stool, abdominal bloating, or a combination of any of the above.
- IBS may be diagnosed when a person has had abdominal pain or discomfort at least 3 times a month for the last 3 months without other disease or injury that could explain the pain.
- the pain or discomfort of IBS may occur with a change in stool frequency or consistency or be relieved by a bowel movement.
- IBS can be classified into four subtypes based on a subject’s usual stool consistency.
- IBS-C IBS with constipation
- IBS-D IBS with diarrhea
- IBS-M mixed IBS
- IBS-U unsubtyped IBS
- a subject with IBS-C may have hard or lumpy stools at least 25 percent of the time, may have loose or watery stools less than 25 percent of the time, or a combination of the two.
- a subject with IBS-D may have loose or watery stools at least 25 percent of the time, hard or lumpy stools less than 25 percent of the time, or a combination of the two.
- a subject with IBS-M may have hard or lumpy stools at least 25 percent of the time and loose or watery stools at least 25 percent of the time.
- a subject with IBS-U may have hard or lumpy stools less than 25 percent of the time, loose or watery stools less than 25 percent of the time, or a combination of the two. Constipation associated with IBS may be due to slow or delayed gastric motility. In some embodiments, the subject with IBS has experienced constipation.
- IBS can be diagnosed in a subject by any methods known in the art or otherwise described herein. For instance, IBS may be diagnosed by a health care provider. The health care provider may conduct a physical exam and may take a medical history of the subject. IBS may be diagnosed if a subject has exhibited one or more symptoms of IBS for at least 3, 4, 5, or 6 months, with one or more symptoms occurring at least three times a month for the previous 3 months. Additional tests that may be useful in the diagnosis of IBS include, but are not limited to: a stool test, lower GI series, flexible sigmoidoscopy, or colonoscopy.
- the term “functional abdominal pain” or “functional abdominal pain syndrome” generally refers to a chronic and or frequently recurring pain not associated with changes in bowel movement patterns or with altered motility in the intestines.
- Normal abdominal activity may be experienced as being painful and contribute to functional abdominal pain.
- Functional abdominal pain may be related to central hypersensitivity, where the brain may fail to regulate pain signals from the gastrointestinal tract. While symptoms of FAPS can appear without apparent cause, they can also occur after infections or events that stimulate the bowel and also after traumatic life events like the death of a loved one, a divorce, or a history of sexual or physical abuse. During times of added stress, symptoms can worsen.
- diarrhea means frequent, poorly formed, loose, watery stools of a subject.
- a subject having diarrhea means the subject is passing loose stools at least three times a day.
- acute diarrhea is a common problem that usually lasts ⁇ 7 days but can last in a protracted or prolonged form for ⁇ 21 days. Diarrhea lasting more than 2 days is often a sign of an enteropathogenic infection.
- chronic diarrhea means diarrhea that lasts at least 4 weeks. Chronic diarrhea symptoms may be continual or intermittent.
- traveler’s diarrhea means diarrheal symptoms associated with travel -related infection. It may be caused by many different organisms, including bacteria such as E.
- coli Salmonella, Shigella, Campylobacter, Aeromonas, Plesiomonas, and vibrios,' parasites such as Giardia, Entamoeba histolytica, Cryptosporidium, and Cyclospora, and viruses.
- symptoms may include nausea, vomiting, abdominal pain, fever, sweats, chills, headache, and malaise.
- Diarrhea may also be the result of food borne enteropathogens.
- Typical food borne pathogens are E. coli, Salmonella, Shigella, Yersinia, and Campylobacter.
- Diarrhea of any duration may cause dehydration, which means the body lacks enough fluid and electrolytes — chemicals in salts, including sodium, potassium, and chloride — to function properly.
- Loose stools contain more water and electrolytes and often weigh more than solid stools.
- idiopathic diarrhea generally refers to diarrhea occurring for unknown reasons. Idiopathic diarrhea generally lasts for less than 5 days and often resolves within 2 or 3 days. Diarrhea generally means an increased frequency or decreased consistency of bowl movements. Diarrhea can also mean an increase in stool weight.
- inflammatory bowel diseases generally refers to chronic inflammation of all or part of the gastrointestinal tract. Symptoms of inflammatory bowel diseases can involve severe diarrhea, pain, abdominal pain and cramping, blood in the subject’s stool, fatigue, reduced appetite and weight loss, or a combination of any of the above. Additional symptoms of inflammatory diseases also include bowel obstruction, ulcers, perforated colon, fistulas, anal fissure, malnutrition, severe dehydration, increased risk of colon cancer.
- Non limiting examples of inflammatory bowel diseases include Crohn’s disease and ulcerative colitis, which itself may have several different subtypes, such as ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis, acute severe ulcerative colitis.
- Inflammatory bowel disease can be diagnosed in a subject by any methods known in the art or otherwise described herein.
- inflammatory bowel disease may be diagnosed by a health care provider.
- a physician or health care provider may perform or order a combination of tests to confirm the presence of inflammatory bowel disease, including, but not limited to, blood tests of anemia or infection, fecal occult blood test, colonoscopy, flexible sigmoidoscopy, upper endoscopy, capsule endoscopy, double-balloon endoscopy, x-ray, computerized tomography scan, magnetic resonance imaging, or small bowel imaging.
- drug induced pain is the unintended effect of a drug, which results in symptoms sufficient to prompt a patient to seek medical attention and/or require hospitalization.
- medications that are known to induce pain include: chemotherapy drugs, which are known to cause nerve damage in the form of peripheral neuropathy. In fact, the onset of peripheral neuropathy can be the primary limiting factor for the amount and duration of the chemotherapy; cholesterol -lowering drugs that people take medications to lower cholesterol levels are known to cause muscle pain and weakness is well known to be a resulting side-effect from cholesterol-lowering drugs; and opioids (hydrocodone, hydromorphone, oxycodone, morphine) when used for years and the pain becomes worse, this vicious pain cycle can be a result of opioid-induced hyperalgesia.
- Malabsorption syndrome occurs when something prevents the bowel from absorbing important nutrients and fluids.
- the problem may be caused by inflammation, disease, or injury. Sometimes, the condition may be the result of the body’s failure to produce enzymes needed to digest some foods.
- Factors that may cause malabsorption syndrome include: antibiotic use; conditions such as celiac disease, chronic pancreatitis, cystic fibrosis, and dairy protein allergies; congenital (birth) defects or diseases of the gall bladder, liver, or pancreas; damage to the intestine (from infection, inflammation, injury, or surgery); and radiation therapy (which may injure the mucosal lining of the bowel).
- Symptoms can include bloating, flatulence, or explosive diarrhea.
- Bile salt malabsorption generally refers increased bile salts in the gastrointestinal tract, which can cause fluid to be pumped into the colon, causing diarrhea. Other symptoms of bile salt malabsorption can also include cramping in the abdomen, smelly wind, weight loss, gall stones, and kidney stones. There are currently three recognized types of bile salt malabsorption: (1) bile salt malabsorption, secondary to ileal resection, or ileal inflammation, (2) idiopathic/primary bile salt malabsorption, and (3) secondary to various gastrointestinal diseases. Bile salt malabsorption can be diagnosed in a subject by any methods known in the art or otherwise described herein. For instance, bile salt malabsorption may be diagnosed by a health care provider.
- a physician or health care provider may perform or order a combination of tests to confirm the presence of bile salt malabsorption, including, but not limited to, a SeHCAT scan, measurement of 7 alpha-hydroxy-4-cholesten-3-one, and fasting blood FGF19 values.
- a therapeutic benefit can mean eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit can be achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the subject, notwithstanding that the subject may still be afflicted with the underlying disorder.
- a prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.
- the compositions may be administered to a subject at risk of developing a particular disease, or to a subject reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made. Therefore, there are varying degrees of treatment or prevention of which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect.
- the inventive methods can provide any amount of any level of treatment or prevention of a GABA-A mediated disease in a mammal.
- the treatment or prevention provided by the inventive method can include treatment or prevention of one or more conditions or symptoms of a disease, e.g., IBS, being treated or prevented.
- the term "subject" refers to any mammal, including, but not limited to, mammals of the order Rodentia, such as mice and hamsters, and mammals of the order Logomorpha, such as rabbits.
- the mammals are from the order Carnivora, including Felines (cats) and Canines (dogs).
- the mammals are from the order Artiodactyla, including Bovines (cows) and Swines (pigs) or of the order Perssodactyla, including Equines (horses).
- the mammals are of the order Primates, Ceboids, or Simoids (monkeys) or of the order Anthropoids (humans and apes).
- the mammal can be a human. In some cases, the subject in not an adult. Accordingly, in some embodiments, the subject is a human.
- alkyl refers to a saturated hydrocarbon chain that is a straight chain or branched chain, containing the indicated number of carbon atoms.
- C1-C4 alkyl group indicates that the group has from 1 to 4 (inclusive) carbon atoms in it.
- C1-C10 alkyl group indicates that the group has from 1 to 10 (inclusive) carbon atoms in it. Unless stated otherwise specifically in the specification, an alkyl group is optionally substituted.
- haloalkyl refers to an alkyl, in which one or more hydrogen atoms is/are replaced with an independently selected halo.
- alkylene refers to a divalent alkyl (e.g., -CH2-).
- alkenyl refers to a hydrocarbon chain that is a straight chain or branched chain, containing the indicated number of carbon atoms having one or more carbon-carbon double bonds.
- C2-C4 alkenyl group indicates that the group has from 2 to 4 (inclusive) carbon atoms in it.
- C2-C10 alkenyl group indicates that the group has from 2 to 10 (inclusive) carbon atoms in it. Unless stated otherwise specifically in the specification, an alkenyl group is optionally substituted.
- alkynyl refers to a hydrocarbon chain that is a straight chain or branched chain, containing the indicated number of carbon atoms having one or more carbon-carbon triple bonds.
- C2-C4 alkynyl group indicates that the group has from 2 to 4 (inclusive) carbon atoms in it.
- C2-C10 alkynyl group indicates that the group has from 2 to 10 (inclusive) carbon atoms in it. Unless stated otherwise specifically in the specification, an alkynyl group is optionally substituted.
- halo or halogen, refers to fluoro, chloro, bromo, or iodo.
- cycloalkyl or “carbocyclic ring” , as used herein, refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which may include fused or bridged ring systems, having from three to fifteen carbon atoms, and which is saturated or unsaturated and attached to the rest of the molecule by a single bond.
- Monocyclic radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
- Polycyclic radicals include, for example, adamantyl, norbomyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like.
- a “cycloalkenyl” is a cycloalkyl comprising one or more carbon-carbon double bonds within the ring. Unless otherwise stated specifically in the specification, a cycloalkyl (or cycloalkenyl) group is optionally substituted.
- heterocyclyl refers to a substituted or unsubstituted 3-, 4-, 5-, 6- or 7-membered saturated or partially unsaturated ring containing one, two, or three heteroatoms, independently selected from oxygen, nitrogen and sulfur (e.g., S, S(O), or S(O)2); heterocyclyl may be unsubstituted or substituted with one or more substituents.
- the heterocyclyl may be optionally fused to another cycloalkyl, heterocyclyl, or an aryl. For example, to a benzo group.
- aryl refers to a hydrocarbon ring system radical comprising, e.g., 6 to 18 carbon atoms and at least one aromatic ring.
- the aryl radical can be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused or bridged ring systems.
- Aryl radicals can include, but not limited to, aryl radicals derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, -indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene.
- aryl or the prefix “ar-“ (such as in “aralkyl”) is meant to include aryl radicals that are optionally substituted.
- heteroaryl refers to a 5- to 14-membered ring system radical comprising one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur (e.g., S, S(O), or S(O)2).
- the heteroaryl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused or bridged ring systems; the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be optionally oxidized; and the nitrogen atom may be optionally quaternized.
- heteroaryl groups may include, but not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodi oxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[Z>][l,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodi oxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[l,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzo
- alkoxy refers to an -O-alkyl radical (e.g., -OCH3).
- haloalkoxy refers to an -O-haloalkyl radical (e.g., -OCF3).
- thioalkoxy refers to an -S-alkyl radical (e.g., -SCH3).
- halothioalkoxy refers to an -S-haloalkyl radical (e.g., -SCF3).
- C(O)glucuronic acid refers to a radical having
- the radical can be:
- Atoms making up the compounds of the present embodiments are intended to include all isotopic forms of such atoms.
- Isotopes include those atoms having the same atomic number but different mass numbers.
- isotopes of hydrogen include tritium and deuterium
- isotopes of carbon include 13 C and 14 C.
- salts of the compounds of Formula (I) used in the method of treatment described herein will be pharmaceutically acceptable salts.
- suitable “pharmaceutically acceptable salts” refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc and the like. Non-limiting examples include ammonium, calcium, magnesium, potassium and sodium salts.
- Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as arginine, betaine caffeine, choline, N,N’l- dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine tripropylamine, tromethamine and the like.
- basic ion exchange resins such as arginine, be
- salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
- acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p- toluenesulfonic acid and the like.
- Non-limiting examples include citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric and tartaric acids.
- a formulation comprising a compound of Formula (I), or a salt, solvate, or stereoisomer thereof, and a suitable pharmaceutically acceptable carrier is provided as understood by a person of ordinary skill in the art.
- a method for treating a patient with IBS comprises the steps of administering one or more compounds of Formula (I), or a salt, solvate, or stereoisomer thereof, or a derivative thereof to a subject.
- the compounds can be provided with a pharmaceutically acceptable carrier, when necessary. Carriers and excipients
- the pharmaceutically acceptable carrier can be any of those conventionally used, and is limited only by physico-chemical considerations, such as solubility and lack of reactivity with the active compound(s), and by the route of administration.
- the pharmaceutically acceptable carriers described herein for example, vehicles, adjuvants, excipients, and diluents, are well- known to those skilled in the art and are readily available to the public.
- the pharmaceutically acceptable carriers include soluble carriers such as known buffers which can be physiologically acceptable (e.g., phosphate buffer) as well as solid compositions such as solid-state carriers or latex beads. It is preferred that the pharmaceutically acceptable carrier be one which is chemically inert to the active agent(s), and one which has little or no detrimental side effects or toxicity under the conditions of use.
- the carriers or diluents used herein may be solid carriers or diluents for solid formulations, liquid carriers or diluents for liquid formulations, or mixtures thereof.
- Solid carriers or diluents include, but are not limited to, gums, starches (e.g., corn starch, pregelatinized starch), sugars (e.g., lactose, mannitol, sucrose, dextrose), cellulosic materials (e.g., microcrystalline cellulose), acrylates (e.g., polymethylacrylate), calcium carbonate, magnesium oxide, talc, or mixtures thereof.
- pharmaceutically acceptable carriers may be, for example, aqueous or non-aqueous solutions, suspensions, emulsions or oils.
- non-aqueous solvents are propylene glycol, polyethylene glycol, and injectable organic esters such as ethyl oleate.
- Aqueous carriers include, for example, water, alcoholic/aqueous solutions, cyclodextrins, emulsions or suspensions, including saline and buffered media.
- oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, mineral oil, olive oil, sunflower oil, fish-liver oil, sesame oil, cottonseed oil, corn oil, olive, petrolatum, and mineral.
- Suitable fatty acids for use in parenteral formulations include, for example, oleic acid, stearic acid, and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters.
- the compounds of this disclosure may further comprise, for example, binders (e.g., acacia, cornstarch, gelatin, carbomer, ethyl cellulose, guar gum, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, povidone), disintegrating agents (e.g., cornstarch, potato starch, alginic acid, silicon dioxide, croscarm elose sodium, crospovidone, guar gum, sodium starch glycolate), buffers (e.g., Tris-HCl, acetate, phosphate) of various pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts), protease inhibitors, surfactants (e.g.
- binders e.g., acacia, cornstarch, gelatin, carbomer, ethyl cellulose, gu
- sodium lauryl sulfate permeation enhancers
- solubilizing agents e.g., cremophor, glycerol, polyethylene glycerol, benzlkonium chloride, benzyl benzoate, cyclodextrins, sorbitan esters, stearic acids
- anti-oxidants e.g., ascorbic acid, sodium metabisulfite, butylated hydroxyanisole
- stabilizers e.g., hydroxypropyl cellulose, hyroxypropylmethyl cellulose
- viscosity increasing agents e.g., carbomer, colloidal silicon dioxide, ethyl cellulose, guar gum
- sweetners e.g., aspartame, citric acid
- preservatives e.g., thimerosal, benzyl alcohol, parabens
- lubricants e.g., stearic acid, magnesium stearate, polyethylene
- the pharmaceutically acceptable carrier comprises more than 90%, more than 80%, more than 70%, more than 60%, more than 50%, more than 40%, more than 30%, more than 20%, more than 10%, more than 9%, more than 8%, more than 6%, more than 5%, more than 4%, more than 3%, more than 2%, more than 1%, more than 0.5%, more than 0.4%, more than 0.3%, more than 0.2%, more than 0.1%, more than 0.09%, more than 0.08%, more than 0.07%, more than 0.06%, more than 0.05%, more than 0.04%, more than 0.03%, more than 0.02%, more than 0.01%, more than 0.009%, more than 0.008%, more than 0.007%, more than 0.006%, more than 0.005%, more than 0.004%, more than 0.003%, more than 0.002%, more than 0.001%, more than 0.0009%, more than 0.0008%, more than 0.0007%, more than 0.0006%, more than 0.0005%, more than 0.004%, more than
- the concentration of the compound in the composition comprises less than 100%, less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 9%, less than 8%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, less than 0.1%, less than 0.09%, less than 0.08%, less than 0.07%, less than 0.06%, less than 0.05%, less than 0.04%, less than 0.03%, less than 0.02%, less than 0.01%, less than 0.009%, less than 0.008%, less than 0.007%, less than 0.006%, less than 0.005%, less than 0.004%, less than 0.003%, less than 0.002%, less than 0.01%, less than 0.009%, less than 0.008%, less than 0.007%, less than 0.006%, less than 0.005%, less
- the concentration of the compound is in the range of about 0.0001% to about 50%, about 0.001% to about 40%, about 0.01% to about 20%, about 0.02% to about 29%, about 0.03% to about 28%, about 0.04% to about 27%, about 0.05% to about 26%, about 0.06% to about 25%, about 0.07% to about 24%, about 0.08% to about 23%, about 0.09% to about 22%, about 0.1% to about 21%, about 0.2% to about 20%, about 0.3% to about 19%, about 0.4% to about 18%, about 0.5% to about 17%, about 0.6% to about 16%, about 0.7% to about 15%, about 0.8% to about 14%, about 0.9% to about 12%, about 1% to about 10% of the pharmaceutical composition by w/w, w/v or v/v.
- the concentration of the compound is in the range of about 0.0001% to about 5%, about 0.001% to about 4%, about 0.01% to about 2%, about 0.02% to about 1%, or about 0.05% to about 0.5% of the pharmaceutical composition by w/w, w/v or v/v.
- the amount of the compound in the pharmaceutical composition is about 0.00001 mg, 0.0001 mg, 0.001 mg, 0.005 mg, 0.01 mg, 0.05 mg, 0.1 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 4 mg, 8 mg, 10 mg, 12 mg, 14 mg, 16 mg, 18 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, 1 g, 1.1 g, 1.2 g, 1.3 g, 1.4 g, 1.5 g, 1.6 g, 1.7 g, 1.8 g, 1.9 g, 2 g, 2.5 g, 3 g
- Administration of a pharmaceutical composition as described herein can be performed by any method that enables delivery of the compound to the site of action.
- the composition may be administered orally, parenterally, enterally, intraperitoneally, topically, transdermally, ophthalmically, intranasally, locally, non-orally, via spray, subcutaneously, intravenously, intratonsillary, intramuscularly, buccally, sublingually, rectally, intravaginally (e.g., via vaginal pessaries, e.g., using methods described in Capra et al. Journal of Pharmaceutics 2013, 386546, which is incorporated herein by reference in its entirety), intraarterially, by infusion, or intrathecally.
- the composition is administered orally.
- the oral administration may comprise administration of any of the oral dosage forms as described herein.
- a composition described herein is administered sublingually.
- a composition described herein is administered transdermally, e.g., via transdermal patch.
- the effective amount of a compound administered will be dependent on the subject being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discretion of the prescribing physician.
- compositions for oral administration are provided.
- the pharmaceutical composition comprising an effective amount of a compound can be formulated for oral administration.
- the pharmaceutical composition comprising an effective amount of a compound for oral administration is a solid pharmaceutical composition.
- the solid pharmaceutical composition may be presented as discrete (e.g., unit) oral dosage forms.
- discrete oral dosage forms include tablets, capsules, caplets, gelatin capsules, sustained release formulations, lozenges, thin films, lollipops, chewing gum.
- the discrete oral dosage form is an orally disintegrating oral dosage form, such as, an orally disintegrating tablet.
- the pharmaceutical composition comprising an effective amount of a compound for oral administration is a liquid pharmaceutical composition.
- liquid compositions for oral administration include hydrophilic suspensions, emulsions, liquids, gels, syrups, slurries, solutions, elixirs, softgels, tinctures, and hydrogels.
- solid or liquid compositions comprising an effective amount of a compound for oral administration comprise various sweetening or flavoring agents, or coloring agents.
- coloring agents include dyes suitable for food such as those known as F.D. & C. dyes and natural coloring agents such as grape skin extract, beet red powder, beta carotene, annato, carmine, turmeric, paprika, and so forth. Derivatives, analogues, and isomers of any of the above colored compound also may be used.
- the choice of carrier will be determined, in part, by the particular compound, as well as by the particular method used to administer the compound. Accordingly, there are a variety of suitable formulations of the pharmaceutical composition of this disclosure.
- the following formulations for parenteral, subcutaneous, intravenous, intramuscular, intraarterial, intrathecal and interperitoneal administration are exemplary, and are in no way limiting. More than one route can be used to administer the compounds, and in certain instances, a particular route can provide a more immediate and more effective response than another route.
- compositions for injection or parenteral administration are provided.
- Parenteral vehicles for subcutaneous, intravenous, intraarterial, or intramuscular injection
- parenteral vehicles include, for example, sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's and fixed oils.
- Formulations suitable for parenteral administration include, for example, aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
- Intravenous vehicles include, for example, fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like.
- sterile liquids such as water and oils, with or without the addition of a surfactant and other pharmaceutically acceptable adjuvants.
- liquid carriers e.g., liquid carriers suitable for injectable solutions
- Suitable soaps for use in parenteral formulations include, for example, fatty alkali metal, ammonium, and triethanolamine salts
- suitable detergents include, for example, (a) cationic detergents such as, for example, dimethyl dialkyl ammonium halides, and alkyl pyridinium halides, (b) anionic detergents such as, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates, (c) nonionic detergents such as, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylenepolypropylene copolymers, (d) amphoteric detergents such as, for example, alkyl-P-aminopropionates, and 2-alkyl- imidazoline quaternary ammonium salts, and (e) mixtures thereof
- the parenteral formulations will typically contain from about 0.5% to about 25% by weight of the compounds in solution. Preservatives and buffers may be used. In order to minimize or eliminate irritation at the site of injection, such compositions may contain one or more nonionic surfactants, for example, having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulations will typically range from about 5% to about 15% by weight. Suitable surfactants include, for example, polyethylene glycol sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.
- HLB hydrophile-lipophile balance
- parenteral formulations can be presented in unit-dose or multi-dose sealed containers, such as ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use.
- sterile liquid excipient for example, water
- Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets.
- injectable formulations are in accordance with this disclosure.
- the requirements for effective pharmaceutical carriers for injectable compositions are well-known to those of ordinary skill in the art (see, e.g., Pharmaceutics and Pharmacy Practice, J.B. Lippincott Company, Philadelphia, PA, Banker and Chalmers, eds., pages 238-250 (1982), and ASHP Handbook on Injectable Drugs, Trissei, 15th ed., pages 622-630 (2009)).
- the compounds of this disclosure can be modified into a depot form, such that the manner in which the compound is released into the body to which it is administered is controlled with respect to time and location within the body (see, for example, U.S. Patent No. 4,450,150).
- Depot forms of compounds can be, for example, an implantable composition comprising the compound and a porous or non-porous material, such as a polymer, wherein the compound is encapsulated by or diffused throughout the material and/or degradation of the non-porous material.
- the depot is then implanted into the desired location within the body and the compounds are released from the implant at a predetermined rate.
- the compounds of this disclosure provided herein can be controlled release compositions, i.e., compositions in which the one or more compounds are released over a period of time after administration.
- Controlled or sustained release compositions include formulation in lipophilic depots (e.g., fatty acids, waxes, oils).
- the composition is an immediate release composition, i.e., a composition in which all or substantially all of the compound is released immediately after administration.
- the compounds of this disclosure can be delivered in a controlled release system.
- the agent may be administered using intravenous infusion, an implantable osmotic pump, a transdermal patch, or other modes of administration.
- a pump may be used.
- polymeric materials can be used.
- a controlled release system can be placed in proximity to the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Design of Controlled Release Drug Delivery Systems, Xiaoling Li and Bhaskara R. Jasti eds. (McGraw-Hill, 2006)).
- the pharmaceutical compositions of this disclosure comprise the compounds of this disclosure, for example, the compounds disclosed herein, and/or their salts, solvates or stereoisomers thereof, and optionally, one or more additional therapeutic agents, such as, for example, 5-HT receptor inhibitors, antibiotics, anti-inflammatory, immunomodulators, together with a pharmaceutically acceptable carrier.
- additional therapeutic agents such as, for example, 5-HT receptor inhibitors, antibiotics, anti-inflammatory, immunomodulators, together with a pharmaceutically acceptable carrier.
- antibiotic agents suitable for use in pharmaceutical composition comprising the compounds heretofore described above and one or more antibiotic agents include, for example, quinolone antibiotics, such as levofloxacin, ciprofloxacin, ibafloxacin, pradofloxacin, rosoxacin, and sarafloxacin.
- quinolone antibiotics such as levofloxacin, ciprofloxacin, ibafloxacin, pradofloxacin, rosoxacin, and sarafloxacin.
- trimethoprimsulfamethoxazole mixtures such as Bactrim®.
- Alternatives include rifaximin and azithromycin. Dosages vary with the weight and age of the subject to be treated. Typically, quinolone antibiotics and trimethoprim-sulfamethoxazole mixtures are given at dosages between 250 and 500 mg daily.
- the dosages are generally between about 5 mg/kg and 25 mg/kg.
- the dosage ranges from 100 mg to about 500 mg (e.g., 200 mg).
- Azithromycin is typically administered at 250-500 mg/day. The dosages required are well within the knowledge of those of ordinary skill in the art.
- the amount or dose of the compounds, salts, solvates, or stereoisomers of any one the compounds of Formula (I), as set forth above, administered should be sufficient to effect, e.g., a therapeutic or prophylactic response, in the subject over a reasonable time frame.
- the dose will be determined by the efficacy of the particular compound and the condition of a human, as well as the body weight of a human to be treated.
- the dosage of the compound can be about 0.001 to about 1000 mg/kg body weight of the subject being treated/day, from about 0.01 to about 100 mg/kg body weight/day, about 0.1 mg to about 10 mg/kg body weight/day.
- Example 1 12-Chloro-9-(2-fluorophenyl)-2,3,8-triazatricyclo[8.4.0.0 2 , 6 ]tetradeca- l(10),3,5,8,l l,13-hexaene-5-carboxylic acid (Compound 102)
- Step 1 Ethyl l-(4-chlorophenyl)-5-methyl-lH-pyrazole-4-carboxylate
- Ethyl acetoacetate (8.06 mL, 1 eq.) was refluxed with A'A -di methyl form am ide dimethyl acetal (10.19 mL, 1 eq.) for 1 hour. After cooling to room temperature the excess DMFDMA was distilled off under reduced pressure. The obtained residue was added to the solution of 4-chlorophenylhydrazine hydrochloride (8 g, 1 eq.) and DIPEA (8.56 mL, 1.1 eq.) in MeOH (100 mL). The resulting solution was refluxed for 3 hours. After cooling to room temperature the solvent was evaporated under reduced pressure.
- Ethyl l-(4-chlorophenyl)-5-methyl-lH-pyrazole-4-carboxylate (4 g, 1 eq.) was dissolved in l,2di chloroethane (20 mL). Palladium trifluoroacetate (0.5 g, 0.1 eq.) was added and the mixture was stirred for 40 minutes, until the solution became clear. Then, tert-butyl hydroperoxide solution (5-6 M in decane, 7.56 mL, 2.5 eq.) and 2-fluorobenzaldehyde (3.18 mL, 2 eq.) were added and the mixture was heated at 90 °C for 20 hours.
- Step 3 Ethyl 5-(bromomethyl)-l-[4-chloro-2-(2-fluorobenzoyl)phenyl]-lH- py razol e-4-carb oxy 1 ate
- Step 4 Ethyl 12-chloro-9-(2-fluorophenyl)-2,3,8-triazatricyclo[8.4.0.0 2 , 6 ] tetradeca- 1(10), 3, 5, 8, 11, 13 -hexaene- 5 -carb oxy late
- Ethyl 5 -(bromomethyl)- 1 - [4-chloro-2-(2-fluorobenzoyl)phenyl] - 1 H-pyrazole-4- carboxylate (480 mg, 1 eq.), ammonium acetate (350 mg, 3 eq.) and urotropine (430 mg, 3 eq.) were dissolved in isopropanol (10 mL) and heated to reflux for 2 hours. After cooling to room temperature the solvent was evaporated and the residue was suspended in water (50 mL). The suspension was extracted with ethyl acetate (3x 30 mL).
- Ethyl 12-chloro-9-(2-fluorophenyl)-2,3,8-triazatricyclo[8.4.0.0 2 , 6 ]tetradeca- l(10),3,5,8,l l,13-hexaene-5-carboxylate (240 mg, 1 eq.) was dissolved in a mixture of THF and water 1 : 1 (6 mL). Lithium hydroxide monohydrate (77 mg, 3 eq.) was added in one portion and the mixture was stirred at 50 °C overnight. Then, THF was evaporated and the resulting solution was acidified with a dilute hydrochloric acid. Resulting precipitate was collected, washed with water (20 mL) and dried under reduced pressure.
- Example 2 was prepared according to methods of Example 1
- Example 3 12-Chloro-9-(2-fluorophenyl)-2,3,4,8-tetraazatricyclo[8.4.0.0 2 , 6 ] tetradeca-l(10),3,5,8,l l,13-hexaene-5-carboxylic acid (Compound 101)
- Step 1 (2-Azido-5-chlorophenyl)(2-fluorophenyl)methanone
- Step 2 Methyl l-[4-chloro-2-(2-fluorobenzoyl)phenyl]-5-(hydroxymethyl)-lH- l,2,3-triazole-4-carboxylate.
- Step 3 Methyl l-[4-chloro-2-(2-fluorobenzoyl)phenyl]-5-[(methanesulfonyl oxy)methyl]- 1H- 1 ,2,3 -triazole-4-carboxylate
- Step 4 Methyl 12-chloro-9-(2-fluorophenyl)-2,3,4,8-tetraazatricyclo[8.4.0.0 2 , 6 ] tetradeca- 1(10), 3, 5, 8, 11, 13 -hexaene- 5 -carb oxy late
- Step 5 12-Chloro-9-(2-fluorophenyl)-2,3,4,8-tetraazatricyclo[8.4.0.0 2 , 6 ]tetradeca- 1(10), 3, 5, 8,1 l,13-hexaene-5-carboxylic acid
- Step 1 ethyl 8-chloro-6-(2-fluorophenyl)-4H-imidazo[l,5-a][l,4]benzodiazepine- 3 -carboxylate
- Step 2 8-chloro-6-(2-fhiorophenyl)-4H-benzo[f]imidazo[l,5-a][l,4]diazepine-3- carboxylic acid
- Cells were incubated at 37°C in a humidified atmosphere with 5% CO2 (rel. humidity about 95%).
- the cells were continuously maintained in and passaged in sterile culture flasks containing a 1 : 1 mixture of Dulbecco’s modified eagle medium and nutrient mixture D-MEM/F-12 (lx, liquid, with L-Glutamine), supplemented with 10% foetal bovine serum and 1.0% Penicillin/Streptomycin solution and neomycin.
- the lx bath solution was made at least every 5 days out of a sterile lOx bath solution, which had been prepared prior to the experimental start of the present study and stored at 1°C to 9°C.
- the final bath solution included Sodium Chloride 137 mM, Potassium Chloride 4 mM, Calcium Chloride 1.8 mM , Magnesium Chloride 1 mM, HEPES 10 mM, D-Glucose 10 mM, pH (NaOH) 7.4.
- the lx intracellular solution was thawed every day and includes Potassium Chloride 130 mM, Magnesium Chloride 1 mM, Mg-ATP 5 mM, HEPES 10 mM, EGTA 5 Mm, pH (KOH) 7.2.
- Automated patch-clamping Cells were transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank during experiments.
- ECso For ECso: + represents that ECso> l 00 nM; ++ represents that EC50 is 50-100 nM; +++ represents that ECso ⁇ 50nM;
- Emax For Emax: + represents that Emax ⁇ 50%; ++ represents that Emax is 50-100%; +++ represents that Emax >100%.
- Example B2 Effects of the compounds and methods of this disclosure on whole gut transit time.
- Example B3 Effects on distal colon transit time.
- Example B4 Effects on stool composition.
- Example B5 Pain sensitivity in IBS mouse model.
- IBS visceral pain model induced by neonatal rectal irritation, is used. Colonic pain sensitivity to graded colorectal balloon distension (CRD, 15, 30, 50 and 70mmHg) is determined by visceromotor response (VMR) measured by electromyography of external oblique muscle. IBS mice show a significant increase in pain sensitivity relative to control mice. IBS mice are treated with a compound of Formula (I) (10 mg/kg). Hyperalgesia in IBS mice is then examined.
- VMR visceromotor response
- Example B6 Measurement of brain and plasma levels.
- a compound of Formula (I) is administered to 5 mice at a dose of lOmg/kg as a solution in 50% propylene glycol by oral gavage (5 ml/kg). After 30 minutes, mice are sacrificed and plasma and brain are harvested. The concentration of the Formula (I) compound in plasma and brain are measured by LC/MS. Average plasma concentrations and brain concentration are examined.
- Example B7 Measurement of GABA-A binding.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof, or an N-oxide thereof), which are positive allosteric modulators of one or more GABA-A receptors, e.g., which are peripherally restricted, positive allosteric modulators of one or more GABA-A receptors; e.g., which are positive allosteric modulators of one or more GABA-A receptors and which selectively target the peripheral nervous system and organs of the body, and which do not substantially pass through the blood-brain barrier. Said compounds are useful e.g., for the treatment of systemic diseases of the body, e.g., diseases in which modulation of one or more peripherally restricted GABA-A receptors is beneficial (e.g., diseases or disorders which are mediated by GABA-A neuronal activity, such as, visceral pain, gut motility, irritable bowel syndrome, functional abdominal pain, functional idiopathic diarrhea, inflammatory bowel diseases (e.g., Crohn's disease), drug induced pain, bile salt malabsorption, lactase or other carbohydrate intolerance, interstitial cystitis, chronic pancreatitis, functional dyspepsia, dysmenorrhea, tactile hypersensitivity, tactile dysfunction, somatic pain, asthma, diabetes, anxiety, social impairment, autism spectrum disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome). In some embodiments, the chemical entities described herein are useful, e.g., for the treatment of diseases, such as irritable bowel syndrome. This disclosure also features pharmaceutical compositions containing the chemical entities described herein as well as methods for the treatment of systemic diseases of the body (e.g., irritable bowel syndrome), which include administering an effective amount of a chemical entity described herein.
Description
PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Patent Application No. 63/370,329, filed on August 3, 2022, which is incorporated herein by reference in its entirety.
TECHNICAL FIELD
[0002] This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof, or an N-oxide thereof), which are positive allosteric modulators of one or more GABA-A receptors, e.g., which are peripherally restricted, positive allosteric modulators of one or more GABA-A receptors; e.g., which are positive allosteric modulators of one or more GABA-A receptors and which selectively target the peripheral nervous system and organs of the body, and which do not substantially pass through the blood-brain barrier. Said compounds are useful e.g., for the treatment of systemic diseases of the body, e.g., diseases in which modulation of one or more peripherally restricted GABA-A receptors is beneficial (e.g., diseases or disorders which are mediated by GABA-A neuronal activity, such as, visceral pain, gut motility, irritable bowel syndrome, functional abdominal pain, functional idiopathic diarrhea, inflammatory bowel diseases (e.g., Crohn’s disease), drug induced pain, bile salt malabsorption, lactase or other carbohydrate intolerance, interstitial cystitis, chronic pancreatitis, functional dyspepsia, dysmenorrhea, tactile hypersensitivity, tactile dysfunction, somatic pain, asthma, diabetes, anxiety, social impairment, autism spectrum disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome). In some embodiments, the chemical entities described herein are useful, e.g., for the treatment of diseases, such as irritable bowel syndrome. This disclosure also features pharmaceutical compositions containing the chemical entities described herein as well as methods for the treatment of systemic diseases of the body (e.g., irritable bowel syndrome), which include administering an effective amount of a chemical entity described herein.
BACKGROUND
[0003] Irritable bowel syndrome (IBS) is a disorder that is defined clinically by intermittent abdominal pain in association with altered bowel movements in the absence of any other structural or inflammatory cause. Based on the dominant bowel pattern, IBS patients are clinically phenotyped into three categories: IBS-D (diarrhea predominant), IBS-C (constipation predominant), and IBS-M (mixed or alternating between diarrhea and constipation). IBS is a very common medical disorder with a prevalence estimated between 6-20% in most developed countries and associated with significant impairment of quality of life and socio-economic costs estimated in the billions of dollars every year.1 Unfortunately, there are few therapeutic options available for patients, with only two approved drugs (lubiprostone and linaclotide) that are both secretagogues and indicated only for symptomatic relief of IBS-C. Currently approved prescription drugs for treatment of IBS-D such as eluxadoline also only provide symptomatic relief with no demonstrated effects on abdominal pain and runs the risk of severe pancreatitis. [0004] The pathogenesis of IBS-D (as with other forms of IBS) remains poorly understood but is thought to be associated with hyperexcitability of neurons, affecting both extrinsic (spinal) and intrinsic (enteric) nerves leading to chronic visceral hypersensitivity and altered motility, respectively. As compared with controls, patients with IBS show increased colonic myoelectrical activity both at baseline and after a meal.2 Suppression of such excitability is therefore a logical therapeutic target. Most pharmacological approaches to the treatment of IBS focus on the role of serotonin (5-HT), released from chemo- and mechanosensitive enterochromaffin cells residing in the mucosa, leading to activation of nociceptive nerves as well as intrinsic primary afferent neurons (IPANs) in the enteric nervous system (ENS) to initiate reflexes for motility and secretion.3 Unfortunately, 5-HT receptor modulators (e.g. tegaserod or alosetron) have only been modestly effective and associated with significant adverse effects leading to their withdrawal from the general market. There is therefore a great need for alternative approaches.4
[0005] Gamma Aminobutyric Acid (GABA) is among the most important inhibitory neurotransmitter in the central nervous system (CNS). Activation of neuronal GABA receptors results in hyperpolarization and stabilization of neuronal excitability. GABA-ergic neurons are also abundant in the enteric nervous system and both GABA-A (inotropic) and GABA-B
(metabotropic) receptors are present in the gut, mediating distinct functional effects.5'13 GABA- B receptor agonists have been investigated for treatment of IBS. 14
[0006] It is thought that the therapeutic benefit of brain penetrating GABA-A modulating benzodiazepines, such as diazepam, in IBS results predominantly from the relief of anxiety that often accompanies IBS.17 The use of brain penetrating benzodiazepines (or other brain penetrating compounds), however, is clinically problematic both because of sedation, and the potential for addiction and physical dependence on chronic use. An alternate approach has been described for tofisopam and its isomer, dextofisopam which is currently under study for IBS. These molecules have been classified as atypical benzodiazepines which enter the CNS and bind to a novel binding site within the central nervous system that may be responsible for mediating its actions.18 19
[0007] GABA-A receptor positive allosteric modulators have heretofore been concerned with CNS conditions like anxiety, insomnia, and epilepsy not IBS.
[0008] WO 2015/200766 discloses positive allosteric modulators of one or more GABA- A receptors, which selectively target the peripheral nervous system and organs of the body, and which do not substantially pass through the blood-brain barrier.
[0009] WO 2020/198275 discloses peripherally-restricted benzodiazepines with reduced blood brain barrier permeability.
SUMMARY
[0010] This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof, or an N-oxide thereof), which are positive allosteric modulators of one or more GABA-A receptors, e.g., which are peripherally restricted, positive allosteric modulators of one or more GABA-A receptors; e.g., which are positive allosteric modulators of one or more GABA-A receptors and which selectively target the peripheral nervous system and organs of the body, and which do not substantially pass through the blood-brain barrier. Said compounds are useful e.g., for the treatment of systemic diseases of the body, e.g., diseases in which modulation of one or more peripherally restricted GABA-A receptors is beneficial (e.g., diseases or disorders which are mediated by GABA-A neuronal activity, such as, visceral
pain, gut motility, irritable bowel syndrome (e.g., Crohn’s disease), functional abdominal pain, functional idiopathic diarrhea, inflammatory bowel diseases, drug induced pain, bile salt malabsorption, lactase or other carbohydrate intolerance, interstitial cystitis, chronic pancreatitis, functional dyspepsia, dysmenorrhea, tactile hypersensitivity, tactile dysfunction, somatic pain, asthma, diabetes, anxiety, social impairment, autism spectrum disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome). In some embodiments, the chemical entities described herein are useful, e.g., for the treatment of diseases, such as irritable bowel syndrome. This disclosure also features pharmaceutical compositions containing the chemical entities described herein as well as methods for the treatment of systemic diseases of the body (e.g., irritable bowel syndrome), which include administering an effective amount of a chemical entity described herein.
[0011] In one aspect, this disclosure provides compounds which are GABA-A receptor positive allosteric modulators that are peripherally-restricted to the GABAergic neurons of the body that are present outside of the brain and central nervous system.
[0013] in which Rla, Rlb, Rlc, Rld, m, R2, A1, A2, X , R4, R5, and Z can be defined anywhere herein.
[0014] In another aspect, this disclosure provides pharmaceutical compositions comprising a compound of Formula (I) as described anywhere herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0015] In another aspect, this disclosure provides methods and uses of the compounds described herein for positive modulation of GABA-A receptors in tissues and organs outside the brain. In some embodiments, said methods can be carried out in vitro. In some embodiments, said methods can be carried out in vivo. Accordingly, in some embodiments,
provided herein is a method of positively modulating GABA-A receptors in tissues and organs outside the brain and central nervous system in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described anywhere herein.
[0016] In another aspect, this disclosure provides methods for treating or preventing (e.g., treating) visceral pain and modulating gut motility, such as in irritable bowel syndrome (e.g., Crohn’s disease), in a subject comprising the administration of a therapeutically effective amount of a peripherally-restricted GABA-A receptor positive allosteric modulator described. Accordingly, in some embodiments, provided herein is a method of treating or preventing (e.g., treating) visceral pain in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described anywhere herein. In some embodiments, provided herein is a method of modulating gut motility in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described anywhere herein.
[0017] In another aspect, this disclosure provides a method of treating irritable bowel syndrome in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described anywhere herein.
[0018] In another aspect, this disclosure provides a method of treating functional abdominal pain, functional idiopathic diarrhea, inflammatory bowel diseases, drug induced pain, bile salt malabsorption, lactase or other carbohydrate intolerance, interstitial cystitis, chronic pancreatitis, functional dyspepsia, dysmenorrhea, tactile hypersensitivity, tactile dysfunction, somatic pain, asthma, diabetes, anxiety, social impairment, autism spectrum disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described anywhere herein.
[0019] In another aspect, this disclosure provides methods for suppressing neuronal excitability in tissues and organs outside of the brain and central nervous system, the method comprising administering to a subject in need of such suppressing a therapeutically effective amount of a chemical entity disclosed anywhere herein (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof, or an N-oxide thereof).
[0020] In another aspect, this disclosure provides compositions comprising compounds for positive modulation of GABA-A receptors in tissues and organs outside the brain as disclosed herein, and at least one additional therapeutic agent.
[0021] In another aspect, this disclosure provides methods and uses of the compositions comprising compounds as disclosed herein, and at least one additional therapeutic agent for positive modulation of GABA-A receptors in tissues and organs outside the brain.
DETAILED DESCRIPTION
[0022] This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof, or an N-oxide thereof), which are positive allosteric modulators of one or more GABA-A receptors, e.g., which are peripherally restricted, positive allosteric modulators of one or more GABA-A receptors; e.g., which are positive allosteric modulators of one or more GABA-A receptors and which selectively target the peripheral nervous system and organs of the body, and which do not substantially pass through the blood-brain barrier. Said compounds are useful e.g., for the treatment of systemic diseases of the body, e.g., diseases in which modulation of one or more peripherally restricted GABA-A receptors is beneficial (e.g., diseases or disorders which are mediated by GABA-A neuronal activity, such as, visceral pain, gut motility, irritable bowel syndrome, functional abdominal pain, functional idiopathic diarrhea, inflammatory bowel diseases (e.g., Crohn’s disease), drug induced pain, bile salt malabsorption, lactase or other carbohydrate intolerance, interstitial cystitis, chronic pancreatitis, functional dyspepsia, dysmenorrhea, tactile hypersensitivity, tactile dysfunction, somatic pain, asthma, diabetes, anxiety, social impairment, autism spectrum disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome). In some embodiments, the chemical entities described herein are useful, e.g., for the treatment of diseases, such as irritable
bowel syndrome. This disclosure also features pharmaceutical compositions containing the chemical entities described herein as well as methods for the treatment of systemic diseases of the body (e.g., irritable bowel syndrome), which include administering an effective amount of a chemical entity described herein.
[0023] The disclosure summarized above may be better understood by referring to the following description. This description of one or more embodiments, set out below to enable one to practice an implementation of this disclosure, is not intended to limit the preferred embodiment, but to serve as a particular example thereof. Those skilled in the art should appreciate that they may readily use the conception and specific embodiments disclosed as a basis for modifying or designing other methods and systems for carrying out the same purposes of this disclosure. Those skilled in the art should also realize that such equivalent assemblies do not depart from the spirit and scope of this disclosure in its broadest form.
Overview
[0024] In one aspect, this disclosure provides methods for treatment of visceral pain and modulating gut motility in a subject, such as that caused by IBS, by positively modulating the GABA-A receptor in the enteric nervous system without the usual CNS side effects of GABA modulation is provided. It is contemplated that the methods described herein are effective in treating visceral pain caused by other ailments, not only IBS. Examples of non-IBS related ailments which can be treated by the inventive methods, include functional abdominal pain, functional idiopathic diarrhea, inflammatory bowel diseases such as Crohn’s disease, drug induced pain, bile salt malabsorption, lactase or other carbohydrate intolerance, interstitial cystitis, chronic pancreatitis, functional dyspepsia, dysmenorrhea, tactile hypersensitivity, somatic pain, asthma, and diabetes.
[0025] In another aspect, this disclosure provides methods for the treatment of tactile dysfunction, anxiety, or social impairment in a subject in need thereof, the method comprising administering to the subject a chemical entity disclosed anywhere herein (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof, or an N-oxide thereof). In some embodiments, the subject is diagnosed with Autism Spectrum Disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome.
[0026] In another aspect, this disclosure provides methods for suppressing neuronal excitability in tissues and organs outside of the brain and central nervous system, the method
comprising administering to a subject in need of such suppressing a therapeutically effective amount of a peripherally-restricted GABA-A receptor positive allosteric modulator, wherein the peripherally-restricted GABA-A receptor positive allosteric modulator is a chemical entity disclosed anywhere herein (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof, or an N-oxide thereof). In some embodiments, neuronal excitability is GABAergic neuronal excitability in tissues and organs outside of the brain and central nervous system. In some embodiments, suppressing neuronal excitability in tissues and organs outside of the brain and central nervous system comprises positively modulating GABA-A receptors in tissues and organs outside the brain and central nervous system. In some embodiments, the peripherally- restricted GABA-A receptor positive allosteric modulator does not substantially cross an intact blood brain barrier of the subject. In some embodiments, less than 50% (e.g., less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, less than 1%, less than 0.5%, or less than 0.1%) of the peripherally-restricted GABA-A receptor positive allosteric modulator crosses an intact blood brain barrier of the subject. In certain embodiments, less than 5% of the peripherally-restricted GABA-A receptor positive allosteric modulator crosses an intact blood brain barrier of the subject. In certain embodiments, less than 1% (e.g., less than 0.5% or less than 0.1%) of the peripherally-restricted GABA-A receptor positive allosteric modulator crosses an intact blood brain barrier of the subject. In some embodiments, the ratio of a concentration of the peripherally -restricted GABA-A receptor positive allosteric modulator in the brain to a concentration of the peripherally-restricted GABA-A receptor positive allosteric modulator in the circulating plasma is about 1 :5. In some embodiments, the ratio of a concentration of the peripherally -restricted GABA-A receptor positive allosteric modulator in the brain to a concentration of the peripherally-restricted GABA-A receptor positive allosteric modulator in the circulating plasma is about 1 :10. In some embodiments, the average concentration of the peripherally -restricted GABA-A receptor positive allosteric modulator in the brain is less than 62.5 nM. In some embodiments, the peripherally-restricted GABA-A receptor positive allosteric modulator binds to the GABA-A receptor with a Ki of less than 500 nM. In some embodiments, upon administration of the peripherally-restricted GABA-A receptor positive allosteric modulator the subject does not experience unwanted sedation side effects. In some embodiments, the peripherally -restricted GABA-A receptor positive allosteric modulator is a pharmaceutically acceptable salt of the compound of Formula (I) (e.g., a
pharmaceutically acceptable salt of a compound delineated in Table Cl). In some embodiments, the peripherally-restricted GABA-A receptor positive allosteric modulator is a compound of Formula (I). For example, the peripherally-restricted GABA-A receptor positive allosteric modulator can be a compound delineated in Table Cl. In some embodiments, the method further comprises administering the peripherally-restricted GABA-A receptor positive allosteric modulator as a pharmaceutical composition comprising the peripherally-restricted GABA-A receptor positive allosteric modulator and a pharmaceutically acceptable carrier. In some embodiments, the method further comprises administering at least one additional therapeutic agent. In some embodiments, the method further comprises administering at least one additional therapeutic agent for positive modulation of GABA-A receptors in tissues and organs outside the brain.
[0027] Through modulation of physical properties such as membrane permeability and incorporation of functional groups known to enhance recognition by blood-brain barrier transporters, GABA-A receptor positive allosteric modulators used in this disclosure, are restricted from the CNS so they do not produce unwanted side effects such as sedation yet still exert beneficial pharmacological effects on the enteric nervous system.
[0028] Pharmacological access to the CNS is restricted by the blood brain barrier (BBB), a system that includes tight junctions between vascular endothelial cells and membrane transporters which work to minimize brain exposure of many circulating biomolecules, peptides, and drugs. Several therapeutically useful drugs take advantage of this restriction to provide a peripheral benefit without CNS complications, such as the well-known non-sedating antihistamines loratadine and cetirizine.20 Since all of the known GABA-A positive allosteric modulators, such as diazepam and midazolam, were designed to treat CNS disorders; non- brain-penetrating analogs have not been generally described, or only described as intermediates toward more useful compounds.
[0029] This disclosure provides, inter alia, chemical compounds according to Formula (I), and pharmaceutically acceptable salts, solvates, and stereoisomers thereof, or any prodrug equivalents (such as esters) thereof, wherein the compound contains a functional group that reduces blood-brain barrier permeability, as shown below.
Accordingly, in one aspect, this disclosure features compounds of Formula (I):
Formula (I) or a pharmaceutically acceptable salt thereof, wherein: each of A1 and A2 is independently selected from the group consisting of N and CR3, provided that one of A1 and A2 is N;
Rla, Rlb, Rlc, and Rld are each independently selected from the group consisting of: H, halo, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, cyano, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 thioalkoxy, C1-6 halothioalkoxy, S(O)2(Ci-6 alkyl), S(=0)(=NH)C I-6 alkyl, Si(Ci-6 alkyl)3, C3-6 cycloalkyl, Ce-io aryl, NR6R7, C(O)R6, and C(O)NR6R7, wherein the C3-6 cycloalkyl and Ce-io aryl are each optionally substituted with from 1- 4 substituents each independently selected from the group consisting of: halo, cyano, C1-6 alkyl, and C1-6 haloalkyl; each R2 is independently selected from the group consisting of: halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, NO2, cyano, C1-6 alkoxy, C1-6 haloalkoxy, SO2(Ci-6 alkyl), S(=0)(=NH)C I-6 alkyl, C3-6 cycloalkyl, NR6R7, C(O)R6, and C(O)NR6R7; m is 0, 1, 2, or 3;
X is selected from the group consisting of: -CO2H, -CH(RX)CO2H, -C(O)Y, - CH(RX)C(O)Y, -S(O)2Y, -CH(RX)S(O)2Y, -(C1-3 alkylene)-N+(Ci-3 alkyl)3, -P(=O)(OH)2, -
XA and XB are independently O, S, N(H), or N(CI-3 alkyl);
Rx is selected from the group consisting of: H, Ci-6 alkyl, -OH, and -NR6R7;
Y is selected from the group consisting of:
(i) -NR6R7;
(ii) -NR8-CH2CH2O-(-CH2CH2O-)n-Y4, wherein n is an integer between 0 and 20; and
(iii) -NR8-Y2-Y3;
Y2 is C2-6 alkylene;
Y3 is selected from the group consisting of: -NR6R7; -NR9S(O)2NR9R10; -S(O)2R6; - S(=O)R6(=NR8); and -P(=O)(Ci-3 alkyl)2;
Y4 is H or C1-6 alkyl;
R3 is selected from the group consisting of:
H; halo; cyano; C1-6 alkyl; C1-6 haloalkyl; C2-6 alkenyl; C2-6 alkynyl; C1-6 alkoxy; C1-6 haloalkoxy; -NR6R7; -C(O)NR6R7; -CH2NR6R7; C3-6 cycloalkyl; Ce-io aryl; and heteroaryl including from 5-6 ring atoms, wherein from 1-4 ring atoms are heteroatoms each independently selected from the group consisting of: N, N(R8), O, and S;
R4 and R5 are independently selected from the group consisting of: H, C1-6 alkyl, -OH, and -NR6R7; or
R4 and R5 taken together with the carbon atom to which each is attached forms a C3-6 cycloalkyl;
each occurrence of R6 and R7 is independently selected from the group consisting of: H, Ci-6 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, -(Ci-4 alkylene)-phenyl, C(=O)R9, C(=O)OR9, and C(=O)NR9R10; or a pair of R6 and R7 on the same nitrogen atom, taken together with said nitrogen atom connecting them, forms a saturated, partially unsaturated, or aromatic ring including 4-8 ring atoms, wherein from 0-2 ring atoms (in addition to the nitrogen atom connecting R6 and R7) are ring heteroatoms each independently selected from the group consisting of: N, N(R8), O, and S; each occurrence of R8 is independently selected from the group consisting of: H, Ci-6 alkyl, -C(=O)R9, -C(=O)OR9, and -C(=O)NR9R10; each occurrence of R9 and R10 is H or Ci-6 alkyl; and
[0033] In some embodiments, one of A1 and A2 is N, and the other of A1 and A2 is CR3.
[0034] In certain embodiments, A1 is N, and A2 is CR3.
[0035] In some embodiments, A2 is N, and A1 is CR3.
[0036] In some embodiments, from one of Rla, Rlb, Rlc, and Rld is an independently selected substituent other than H.
[0037] In some embodiments, A1 and A2 are both N.
[0038] In some embodiments, from 1-2 of Rla, Rlb, Rlc, and Rld is an independently selected substituent other than H. In certain embodiments, one of Rla, Rlb, Rlc, and Rld is selected from the group consisting of: C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ci- 6 alkoxy, C1-6 haloalkoxy, C1-6 thioalkoxy, C1-6 halothioalkoxy, and C3-6 cycloalkyl; and the other three of Rla, Rlb, Rlc, and Rld are H.
[0039] In some embodiments, one of Rla, Rlb, Rlc, and Rld is C1-6 alkyl; and the other three of Rla, Rlb, Rlc, and Rld are H.
[0040] In some embodiments, one of Rla, Rlb, Rlc, and Rld is selected from the group consisting of: halo, cyano, S(O)2(Ci-6 alkyl), S(=O)(=NH)CI-6 alkyl, NR6R7, C(O)R6, and C(O)NR6R7; and the other three of Rla, Rlb, Rlc, and Rld are H. In certain embodiments, one of Rla, Rlb, Rlc, and Rld is halo; and the other three of Rla, Rlb, Rlc, and Rld are H.
[0041] In some embodiments, Rlc is selected from the group consisting of: C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 thioalkoxy, C1-6 halothioalkoxy, and C3-6 cycloalkyl.
[0042] In some embodiments, m is 1 or 2. In certain embodiments, m is 1.
[0044] In some embodiments, each R2 is independently selected from the group consisting of: halo, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, NO2, cyano, C1-6 alkoxy, C1-6 haloalkoxy, SO2(Ci-6 alkyl), and C3-6 cycloalkyl.
[0045] In certain embodiments, each R2 is independently selected from the group consisting of: halo, C1-6 alkyl, C1-6 haloalkyl, cyano, C1-6 alkoxy, and C1-6 haloalkoxy.
[0046] In certain embodiments, each R2 is an independently selected halo, optionally -F, -Cl, or -Br.
[0047] In some embodiments, each of R4 and R5 is H.
[0048] In some embodiments, one of R4 and R5 is Ci-6 alkyl (e.g., CH3); and the other of R4 and R5 is H.
[0049] In some embodiments, X is -CO2H or -CH(RX)CO2H.
[0050] In certain embodiments, X is -CO2H.
[0051] In some embodiments, X is -C(O)Y or -CH(RX)C(O)Y.
[0052] In certain embodiments, X is -C(O)Y.
[0053] In some embodiments, Y is -NR6R7, such as wherein Y is NH2, NH(CI-3 alkyl), or N(CI-3 alkyl)2.
[0054] In certain embodiments, Y is -NR8-Y2-Y3.
[0055] In certain embodiments, Y is -N(H)-Y2-Y3.
[0056] In certain embodiments, Y2 is straight-chain C2-4 alkylene, such as -CH2CH2- or - CH2CH2CH2-.
[0057] In certain embodiments, Y3 is NR6R7, such as NHC(=O)NR9R10, such as NHC(=O)NH2.
[0058] In some embodiments, Y3 is -NR9S(O)2NR9R10, such as -NHS(O)2NH2.
[0059] In some embodiments, R3 is H.
[0060] In some embodiments, R3 is halo, such as -Cl or -Br.
[0061] In some embodiments, R3 is C1-6 alkyl or C1-6 haloalkyl, such as wherein R3 is Ci-
3 alkyl, such as methyl.
[0062] In some embodiments,
• one of Rla, Rlb, Rlc, and Rld is C1-6 alkyl, cyano, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 thioalkoxy, C1-6 halothioalkoxy, or halo (e.g., Br or -Cl); optionally Rlc is C1-6 alkyl or halo (e.g., Br or -Cl);
• the other three of Rla, Rlb, Rlc, and Rld are H;
• m is 1 or 2 (e.g., 1);
• each R2 is an independently selected halo, such as -F, -Cl, or -Br; and
• A1 is N, and A2 is CR3; or A2 is N, and A1 is CR3; or A1 is N, and A2 is N.
[0063] In some embodiments,
• one of Rla, Rlb, Rlc, and Rld is Ci-6 alkyl or halo (e.g., Br or -Cl); optionally Rlc is Ci-6 alkyl or halo (e.g., Br or -Cl);
• the other three of Rla, Rlb, Rlc, and Rld are H;
• m is 1 or 2 (e.g., 1);
• each R2 is an independently selected halo, such as -F, -Cl, or -Br; and
• A1 is N, and A2 is CR3; or A2 is N, and A1 is CR3; or A1 is N, and A2 is N.
[0064] In some embodiments, one of Rla, Rlb, Rlc, and Rld is Ci-6 alkyl, optionally Rlc is Ci-6 alkyl.
[0065] In some embodiments, one of Rla, Rlb, Rlc, and Rld is halo (e.g., Br or -Cl), optionally Rlc is halo (e.g., Br or -Cl).
[0066] In some embodiments, m is 1.
[0067] In some embodiments, wherein R3 is H.
[0068] In some embodiments, R4 and R5 are each H.
[0069] In some embodiments, one of R4 and R5 is Ci-6 alkyl (e.g., CH3); and the other of
R4 and R5 is H.
[0070] In some embodiments, X is -CO2H or -CH(RX)CO2H.
[0071] In some embodiments, X is -CO2H.
[0072] In some embodiments, Z is a lone pair of electrons. v°
[0073] In some embodiments, Z is ' e
[0074] In certain embodiments, the compound is selected from the group consisting of the compounds in Table Cl, or a pharmaceutically acceptable salt thereof.
[0075] In another aspect, this disclosure provides pharmaceutical compositions comprising the compounds of Formula (I), as described herein, and a pharmaceutically acceptable carrier. [0076] In a further aspect, this disclosure provides a salt (e.g., a pharmaceutically acceptable salt) of the Formula (I) compounds described herein.
Definitions
[0077] As used herein, the chemical terms used above are standard chemical terminology. Sample definitions of such chemical substituents can be found in U.S. Patent 8,530,438; which is incorporated herein by reference in its entirety.
[0078] As used herein, “peripherally restricted” or “restricted access to the central nervous system” generally refers to a chemical entity (e.g., a compound or a pharmaceutically acceptable thereof) that does not substantially cross an intact blood brain barrier of a subject. The term also encompasses compounds that may cross an intact blood brain barrier, but upon administration is rapidly metabolized to a form that does not substantially cross an intact blood brain barrier of the subject. A compound may be considered “peripherally restricted” if, upon
administration to a subject, less than 50%, less than 45%, less than 40%, less than 35%, less than 30%, less than 25%, less than 20%, less than 15%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.1% of the compound crosses an intact blood brain barrier of the subject. In some embodiments, the term “peripherally restricted can mean that the concentration of a compound in the brain compared to the concentration in the circulating plasma (braimplasma) ratio of about 1 :5 or greater (e.g., about 1 : 10 or greater). In one exemplary embodiment the braimplasma ratio is determined by measuring the ratio of a compound in mice or rats.
[0079] As used herein, the term “an effective amount” or “a therapeutically effective amount” refers to the amount of a compound that is sufficient to affect the intended application, including but not limited to disease treatment, as defined below. The therapeutically effective amount may vary depending upon the intended treatment application (in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The term also applies to a dose that will induce a particular response in target cells. The specific dose will vary depending on the particular compounds chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried.
[0080] As used herein, the term “positive modulation” or “positive allosteric modulation” and all words stemming therefrom, refer to compounds that bind to an allosteric site on a receptor complex and affect it in a positive manner. Affecting a receptor in a positive manner typically means causing increased efficiency of the main receptor site. Increased receptor efficiency can mean potentially inducing a receptor to undergo a conformational change, or where the channel opens more frequently or for longer periods of time when an agonist binds to the receptor.
[0081] As used herein, “visceral pain” refers to pain that results from the activation of nociceptors of the thoracic, pelvic, or abdominal organs. Problems with organs, for example but not limited to, the stomach, kidney, gallbladder, urinary bladder, pancreas, and intestines, can lead to visceral pain. Such problems can include distension, perforation, inflammation,
impaction, and constipation. The visceral pain can be diffuse, vague, dull, deep, squeezing, pressure-like, and difficult to localize. The visceral pain may be accompanied by symptoms such as nausea, vomiting, sweating, and changes in blood pressure, heart rate, and temperature. Visceral pain can often be experienced, or “referred” to different sites of the body. In some embodiments, visceral pain can be associated with functional dyspepsia, interstitial cystitis, chronic pancreatitis, or dysmenorrhea.
[0082] As used herein, “gut motility” refers to stretching and contractions of the muscles of the gastrointestinal tract. Peristaltic movement is the cyclical relaxation of circular smooth muscles, followed by their longitudinal contraction. Gut motility can be impaired, which can lead to abnormal contractions, including spasms and paralysis.
[0083] As used herein, “irritable bowel syndrome” or “IBS” generally refers to a syndrome in which subjects experience recurrent or chronic gastrointestinal symptoms. Symptoms of IBS can include, e.g., abdominal pain, abdominal discomfort, constipation, diarrhea, mucus in the stool, abdominal bloating, or a combination of any of the above. IBS may be diagnosed when a person has had abdominal pain or discomfort at least 3 times a month for the last 3 months without other disease or injury that could explain the pain. The pain or discomfort of IBS may occur with a change in stool frequency or consistency or be relieved by a bowel movement. IBS can be classified into four subtypes based on a subject’s usual stool consistency. The four subtypes of IBS are: IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), mixed IBS (IBS-M), and unsubtyped IBS (IBS-U). A subject with IBS-C may have hard or lumpy stools at least 25 percent of the time, may have loose or watery stools less than 25 percent of the time, or a combination of the two. A subject with IBS-D may have loose or watery stools at least 25 percent of the time, hard or lumpy stools less than 25 percent of the time, or a combination of the two. A subject with IBS-M may have hard or lumpy stools at least 25 percent of the time and loose or watery stools at least 25 percent of the time. A subject with IBS-U may have hard or lumpy stools less than 25 percent of the time, loose or watery stools less than 25 percent of the time, or a combination of the two. Constipation associated with IBS may be due to slow or delayed gastric motility. In some embodiments, the subject with IBS has experienced constipation. IBS can be diagnosed in a subject by any methods known in the art or otherwise described herein. For instance, IBS may be diagnosed by a health care provider. The health care provider may conduct a physical exam and may take a medical history of the subject. IBS
may be diagnosed if a subject has exhibited one or more symptoms of IBS for at least 3, 4, 5, or 6 months, with one or more symptoms occurring at least three times a month for the previous 3 months. Additional tests that may be useful in the diagnosis of IBS include, but are not limited to: a stool test, lower GI series, flexible sigmoidoscopy, or colonoscopy.
[0084] The term “functional abdominal pain” or “functional abdominal pain syndrome” (FAPS) generally refers to a chronic and or frequently recurring pain not associated with changes in bowel movement patterns or with altered motility in the intestines. Normal abdominal activity may be experienced as being painful and contribute to functional abdominal pain. Functional abdominal pain may be related to central hypersensitivity, where the brain may fail to regulate pain signals from the gastrointestinal tract. While symptoms of FAPS can appear without apparent cause, they can also occur after infections or events that stimulate the bowel and also after traumatic life events like the death of a loved one, a divorce, or a history of sexual or physical abuse. During times of added stress, symptoms can worsen.
[0085] Repeated injury in the abdomen can cause nerve receptors to become overly sensitive. For instance, if someone has had multiple abdominal surgeries or an infection, a later painful occurrence may be experienced as more painful than previously. Even normal abdominal activity may be experienced as being painful. It is as if the volume has been turned up on a stereo receiver. This condition is called visceral hypersensitivity (i.e., increased sensitivity of the intestines). Furthermore although the brain has an ability to "turn down" the pain signals from the GI tract with FAPS, this ability is reduced, so even small amounts of intestinal disturbance can be amplified to produce severe pain (central hypersensitivity). So these individuals have an altered "braingut axis" where there is a failure of the brain to regulate even normal gut nerve activity leading to increased pain.
[0086] For purposes of this disclosure, the term “diarrhea,” as used herein means frequent, poorly formed, loose, watery stools of a subject. A subject having diarrhea means the subject is passing loose stools at least three times a day. The term “acute diarrhea” is a common problem that usually lasts < 7 days but can last in a protracted or prolonged form for <21 days. Diarrhea lasting more than 2 days is often a sign of an enteropathogenic infection. The term “chronic diarrhea” means diarrhea that lasts at least 4 weeks. Chronic diarrhea symptoms may be continual or intermittent. The term “traveler’s diarrhea” means diarrheal symptoms associated with travel -related infection. It may be caused by many different organisms,
including bacteria such as E. coli, Salmonella, Shigella, Campylobacter, Aeromonas, Plesiomonas, and vibrios,' parasites such as Giardia, Entamoeba histolytica, Cryptosporidium, and Cyclospora, and viruses. In addition to diarrhea, symptoms may include nausea, vomiting, abdominal pain, fever, sweats, chills, headache, and malaise. Diarrhea may also be the result of food borne enteropathogens. Typical food borne pathogens are E. coli, Salmonella, Shigella, Yersinia, and Campylobacter.
[0087] Diarrhea of any duration may cause dehydration, which means the body lacks enough fluid and electrolytes — chemicals in salts, including sodium, potassium, and chloride — to function properly. Loose stools contain more water and electrolytes and often weigh more than solid stools.
[0088] The term “functional idiopathic diarrhea” generally refers to diarrhea occurring for unknown reasons. Idiopathic diarrhea generally lasts for less than 5 days and often resolves within 2 or 3 days. Diarrhea generally means an increased frequency or decreased consistency of bowl movements. Diarrhea can also mean an increase in stool weight.
[0089] The term “inflammatory bowel diseases” generally refers to chronic inflammation of all or part of the gastrointestinal tract. Symptoms of inflammatory bowel diseases can involve severe diarrhea, pain, abdominal pain and cramping, blood in the subject’s stool, fatigue, reduced appetite and weight loss, or a combination of any of the above. Additional symptoms of inflammatory diseases also include bowel obstruction, ulcers, perforated colon, fistulas, anal fissure, malnutrition, severe dehydration, increased risk of colon cancer. Non limiting examples of inflammatory bowel diseases include Crohn’s disease and ulcerative colitis, which itself may have several different subtypes, such as ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis, acute severe ulcerative colitis. Inflammatory bowel disease can be diagnosed in a subject by any methods known in the art or otherwise described herein. For instance, inflammatory bowel disease may be diagnosed by a health care provider. A physician or health care provider may perform or order a combination of tests to confirm the presence of inflammatory bowel disease, including, but not limited to, blood tests of anemia or infection, fecal occult blood test, colonoscopy, flexible sigmoidoscopy, upper endoscopy, capsule endoscopy, double-balloon endoscopy, x-ray, computerized tomography scan, magnetic resonance imaging, or small bowel imaging.
[0090] The term “drug induced pain” is the unintended effect of a drug, which results in symptoms sufficient to prompt a patient to seek medical attention and/or require hospitalization. Examples of medications that are known to induce pain include: chemotherapy drugs, which are known to cause nerve damage in the form of peripheral neuropathy. In fact, the onset of peripheral neuropathy can be the primary limiting factor for the amount and duration of the chemotherapy; cholesterol -lowering drugs that people take medications to lower cholesterol levels are known to cause muscle pain and weakness is well known to be a resulting side-effect from cholesterol-lowering drugs; and opioids (hydrocodone, hydromorphone, oxycodone, morphine) when used for years and the pain becomes worse, this vicious pain cycle can be a result of opioid-induced hyperalgesia.
[0091] Proteins, carbohydrates, fats, and most fluids are absorbed in the small intestine (small bowel). Malabsorption syndrome occurs when something prevents the bowel from absorbing important nutrients and fluids. The problem may be caused by inflammation, disease, or injury. Sometimes, the condition may be the result of the body’s failure to produce enzymes needed to digest some foods. Factors that may cause malabsorption syndrome include: antibiotic use; conditions such as celiac disease, chronic pancreatitis, cystic fibrosis, and dairy protein allergies; congenital (birth) defects or diseases of the gall bladder, liver, or pancreas; damage to the intestine (from infection, inflammation, injury, or surgery); and radiation therapy (which may injure the mucosal lining of the bowel). Symptoms can include bloating, flatulence, or explosive diarrhea.
[0092] The term “bile salt malabsorption” generally refers increased bile salts in the gastrointestinal tract, which can cause fluid to be pumped into the colon, causing diarrhea. Other symptoms of bile salt malabsorption can also include cramping in the abdomen, smelly wind, weight loss, gall stones, and kidney stones. There are currently three recognized types of bile salt malabsorption: (1) bile salt malabsorption, secondary to ileal resection, or ileal inflammation, (2) idiopathic/primary bile salt malabsorption, and (3) secondary to various gastrointestinal diseases. Bile salt malabsorption can be diagnosed in a subject by any methods known in the art or otherwise described herein. For instance, bile salt malabsorption may be diagnosed by a health care provider. A physician or health care provider may perform or order a combination of tests to confirm the presence of bile salt malabsorption, including, but not
limited to, a SeHCAT scan, measurement of 7 alpha-hydroxy-4-cholesten-3-one, and fasting blood FGF19 values.
[0093] The terms "treat" and "prevent" as well as words stemming therefrom, as used herein, refer to an approach for obtaining beneficial or desired results including but not limited to a therapeutic benefit and/or a prophylactic benefit. A therapeutic benefit can mean eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit can be achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the subject, notwithstanding that the subject may still be afflicted with the underlying disorder. A prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof. For prophylactic benefit, the compositions may be administered to a subject at risk of developing a particular disease, or to a subject reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made. Therefore, there are varying degrees of treatment or prevention of which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect. In this respect, the inventive methods can provide any amount of any level of treatment or prevention of a GABA-A mediated disease in a mammal. Furthermore, the treatment or prevention provided by the inventive method can include treatment or prevention of one or more conditions or symptoms of a disease, e.g., IBS, being treated or prevented.
[0094] As used herein, the term "subject" refers to any mammal, including, but not limited to, mammals of the order Rodentia, such as mice and hamsters, and mammals of the order Logomorpha, such as rabbits. In some embodiments, the mammals are from the order Carnivora, including Felines (cats) and Canines (dogs). In some embodiments, the mammals are from the order Artiodactyla, including Bovines (cows) and Swines (pigs) or of the order Perssodactyla, including Equines (horses). In some embodiments, the mammals are of the order Primates, Ceboids, or Simoids (monkeys) or of the order Anthropoids (humans and apes). As a non-limiting example, the mammal can be a human. In some cases, the subject in not an adult. Accordingly, in some embodiments, the subject is a human.
[0095] The term “alkyl,” as used herein, refers to a saturated hydrocarbon chain that is a straight chain or branched chain, containing the indicated number of carbon atoms. For example, C1-C4 alkyl group indicates that the group has from 1 to 4 (inclusive) carbon atoms in it. Similarly, C1-C10 alkyl group indicates that the group has from 1 to 10 (inclusive) carbon atoms in it. Unless stated otherwise specifically in the specification, an alkyl group is optionally substituted. The term "haloalkyl", as used herein, refers to an alkyl, in which one or more hydrogen atoms is/are replaced with an independently selected halo.
[0096] The term "alkylene" refers to a divalent alkyl (e.g., -CH2-).
[0097] The term “alkenyl,” as used herein, refers to a hydrocarbon chain that is a straight chain or branched chain, containing the indicated number of carbon atoms having one or more carbon-carbon double bonds. For example, C2-C4 alkenyl group indicates that the group has from 2 to 4 (inclusive) carbon atoms in it. Similarly, C2-C10 alkenyl group indicates that the group has from 2 to 10 (inclusive) carbon atoms in it. Unless stated otherwise specifically in the specification, an alkenyl group is optionally substituted.
[0098] The term “alkynyl,” as used herein, refers to a hydrocarbon chain that is a straight chain or branched chain, containing the indicated number of carbon atoms having one or more carbon-carbon triple bonds. For example, C2-C4 alkynyl group indicates that the group has from 2 to 4 (inclusive) carbon atoms in it. Similarly, C2-C10 alkynyl group indicates that the group has from 2 to 10 (inclusive) carbon atoms in it. Unless stated otherwise specifically in the specification, an alkynyl group is optionally substituted.
[0099] The term “halo” or “halogen,” as used herein, refers to fluoro, chloro, bromo, or iodo.
[00100] The term “cycloalkyl” or “carbocyclic ring” , as used herein, refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which may include fused or bridged ring systems, having from three to fifteen carbon atoms, and which is saturated or unsaturated and attached to the rest of the molecule by a single bond. Monocyclic radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic radicals include, for example, adamantyl, norbomyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. A “cycloalkenyl” is a cycloalkyl comprising one or more carbon-carbon double bonds within the ring. Unless
otherwise stated specifically in the specification, a cycloalkyl (or cycloalkenyl) group is optionally substituted.
[00101] The term “heterocyclyl”, “heterocycloalkyl”, or “heterocyclic ring” refers to a substituted or unsubstituted 3-, 4-, 5-, 6- or 7-membered saturated or partially unsaturated ring containing one, two, or three heteroatoms, independently selected from oxygen, nitrogen and sulfur (e.g., S, S(O), or S(O)2); heterocyclyl may be unsubstituted or substituted with one or more substituents. The heterocyclyl may be optionally fused to another cycloalkyl, heterocyclyl, or an aryl. For example, to a benzo group.
[00102] The term “aryl”, as used herein, refers to a hydrocarbon ring system radical comprising, e.g., 6 to 18 carbon atoms and at least one aromatic ring. The aryl radical can be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused or bridged ring systems. Aryl radicals can include, but not limited to, aryl radicals derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, -indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. Unless stated otherwise specifically in the specification, the term “aryl” or the prefix “ar-“ (such as in “aralkyl”) is meant to include aryl radicals that are optionally substituted.
[00103] The term “heteroaryl”, as used herein, refers to a 5- to 14-membered ring system radical comprising one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur (e.g., S, S(O), or S(O)2). The heteroaryl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused or bridged ring systems; the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be optionally oxidized; and the nitrogen atom may be optionally quaternized. Exemplary heteroaryl groups may include, but not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodi oxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[Z>][l,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodi oxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[l,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-
oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, 1 -phenyl- 177-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e., thienyl). Unless stated otherwise specifically in the specification, a heteroaryl group is optionally substituted.
[00104] The term "alkoxy", as used herein, refers to an -O-alkyl radical (e.g., -OCH3). The term “haloalkoxy”, as used herein, refers to an -O-haloalkyl radical (e.g., -OCF3).
[00105] The term “thioalkoxy”, as used herein, refers to an -S-alkyl radical (e.g., -SCH3). The term “halothioalkoxy”, as used herein refers to an -S-haloalkyl radical (e.g., -SCF3). [00106] The term “C(O)glucuronic acid”, as used herein, refers to a radical having
HCL /O
[00107] Atoms making up the compounds of the present embodiments are intended to include all isotopic forms of such atoms. Isotopes, as used herein, include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium, and isotopes of carbon include 13C and 14C.
Exemplary pharmaceutical compositions
[00108] Accordingly, included within the compounds of this disclosure are the tautomeric forms of the disclosed compounds, isomeric forms including enantiomers, stereoisomers, and diastereoisomers, and the pharmaceutically-acceptable salts thereof.
[00109] The salts of the compounds of Formula (I) used in the method of treatment described herein will be pharmaceutically acceptable salts. A person of ordinary skill in the art would recognize that non-pharmaceutically acceptable salts may be used as intermediaries in the preparation of the compounds of Formula (I) or its derivatives and their pharmaceutically acceptable salts. When the compound of this disclosure is acidic, suitable "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include
aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc and the like. Non-limiting examples include ammonium, calcium, magnesium, potassium and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as arginine, betaine caffeine, choline, N,N’l- dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine tripropylamine, tromethamine and the like.
[00110] When the compound of this disclosure is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p- toluenesulfonic acid and the like. Non-limiting examples include citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric and tartaric acids. In a further embodiment of this disclosure, a formulation comprising a compound of Formula (I), or a salt, solvate, or stereoisomer thereof, and a suitable pharmaceutically acceptable carrier is provided as understood by a person of ordinary skill in the art.
[00111] In yet a further aspect of this disclosure, a method for treating a patient with IBS is provided. The method comprises the steps of administering one or more compounds of Formula (I), or a salt, solvate, or stereoisomer thereof, or a derivative thereof to a subject. The compounds can be provided with a pharmaceutically acceptable carrier, when necessary. Carriers and excipients
[00112] With respect to pharmaceutical compositions described herein, the pharmaceutically acceptable carrier can be any of those conventionally used, and is limited only by physico-chemical considerations, such as solubility and lack of reactivity with the active compound(s), and by the route of administration. The pharmaceutically acceptable carriers described herein, for example, vehicles, adjuvants, excipients, and diluents, are well-
known to those skilled in the art and are readily available to the public. Examples of the pharmaceutically acceptable carriers include soluble carriers such as known buffers which can be physiologically acceptable (e.g., phosphate buffer) as well as solid compositions such as solid-state carriers or latex beads. It is preferred that the pharmaceutically acceptable carrier be one which is chemically inert to the active agent(s), and one which has little or no detrimental side effects or toxicity under the conditions of use.
[00113] The carriers or diluents used herein may be solid carriers or diluents for solid formulations, liquid carriers or diluents for liquid formulations, or mixtures thereof.
[00114] Solid carriers or diluents include, but are not limited to, gums, starches (e.g., corn starch, pregelatinized starch), sugars (e.g., lactose, mannitol, sucrose, dextrose), cellulosic materials (e.g., microcrystalline cellulose), acrylates (e.g., polymethylacrylate), calcium carbonate, magnesium oxide, talc, or mixtures thereof.
[00115] For liquid formulations, pharmaceutically acceptable carriers may be, for example, aqueous or non-aqueous solutions, suspensions, emulsions or oils. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, and injectable organic esters such as ethyl oleate. Aqueous carriers include, for example, water, alcoholic/aqueous solutions, cyclodextrins, emulsions or suspensions, including saline and buffered media.
[00116] Examples of oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, mineral oil, olive oil, sunflower oil, fish-liver oil, sesame oil, cottonseed oil, corn oil, olive, petrolatum, and mineral. Suitable fatty acids for use in parenteral formulations include, for example, oleic acid, stearic acid, and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters.
[00117] In addition, in some embodiments, the compounds of this disclosure may further comprise, for example, binders (e.g., acacia, cornstarch, gelatin, carbomer, ethyl cellulose, guar gum, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, povidone), disintegrating agents (e.g., cornstarch, potato starch, alginic acid, silicon dioxide, croscarm elose sodium, crospovidone, guar gum, sodium starch glycolate), buffers (e.g., Tris-HCl, acetate, phosphate) of various pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts), protease inhibitors, surfactants (e.g. sodium lauryl sulfate), permeation enhancers, solubilizing agents (e.g., cremophor, glycerol, polyethylene glycerol, benzlkonium chloride, benzyl benzoate,
cyclodextrins, sorbitan esters, stearic acids), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite, butylated hydroxyanisole), stabilizers (e.g., hydroxypropyl cellulose, hyroxypropylmethyl cellulose), viscosity increasing agents (e.g., carbomer, colloidal silicon dioxide, ethyl cellulose, guar gum), sweetners (e.g., aspartame, citric acid), preservatives (e.g., thimerosal, benzyl alcohol, parabens), lubricants (e.g., stearic acid, magnesium stearate, polyethylene glycol, sodium lauryl sulfate), flow-aids (e.g., colloidal silicon dioxide), plasticizers (e.g., diethyl phthalate, triethyl citrate), emulsifiers (e.g., carbomer, hydroxypropyl cellulose, sodium lauryl sulfate), polymer coatings (e.g., poloxamers or poloxamines), coating and film forming agents (e.g., ethyl cellulose, acrylates, polymethacrylates), and/or adjuvants. [00118] In some embodiments, the pharmaceutically acceptable carrier comprises more than 90%, more than 80%, more than 70%, more than 60%, more than 50%, more than 40%, more than 30%, more than 20%, more than 10%, more than 9%, more than 8%, more than 6%, more than 5%, more than 4%, more than 3%, more than 2%, more than 1%, more than 0.5%, more than 0.4%, more than 0.3%, more than 0.2%, more than 0.1%, more than 0.09%, more than 0.08%, more than 0.07%, more than 0.06%, more than 0.05%, more than 0.04%, more than 0.03%, more than 0.02%, more than 0.01%, more than 0.009%, more than 0.008%, more than 0.007%, more than 0.006%, more than 0.005%, more than 0.004%, more than 0.003%, more than 0.002%, more than 0.001%, more than 0.0009%, more than 0.0008%, more than 0.0007%, more than 0.0006%, more than 0.0005%, more than 0.0004%, more than 0.0003%, more than 0.0002%, or more than 0.0001% of the pharmaceutical composition by w/w, w/v or v/v.
[00119] In some embodiments, the concentration of the compound in the composition comprises less than 100%, less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 9%, less than 8%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, less than 0.1%, less than 0.09%, less than 0.08%, less than 0.07%, less than 0.06%, less than 0.05%, less than 0.04%, less than 0.03%, less than 0.02%, less than 0.01%, less than 0.009%, less than 0.008%, less than 0.007%, less than 0.006%, less than 0.005%, less than 0.004%, less than 0.003%, less than 0.002%, less than 0.001%, less than 0.0009%, less than 0.0008%, less than 0.0007%, less than 0.0006%, less than 0.0005%, less than 0.0004%, less than 0.0003%, less than 0.0002%, or less than 0.0001% of the pharmaceutical composition by w/w, w/v or v/v.
[00120] In some embodiments, the concentration of the compound is in the range of about 0.0001% to about 50%, about 0.001% to about 40%, about 0.01% to about 20%, about 0.02% to about 29%, about 0.03% to about 28%, about 0.04% to about 27%, about 0.05% to about 26%, about 0.06% to about 25%, about 0.07% to about 24%, about 0.08% to about 23%, about 0.09% to about 22%, about 0.1% to about 21%, about 0.2% to about 20%, about 0.3% to about 19%, about 0.4% to about 18%, about 0.5% to about 17%, about 0.6% to about 16%, about 0.7% to about 15%, about 0.8% to about 14%, about 0.9% to about 12%, about 1% to about 10% of the pharmaceutical composition by w/w, w/v or v/v.
[00121] In some embodiments, the concentration of the compound is in the range of about 0.0001% to about 5%, about 0.001% to about 4%, about 0.01% to about 2%, about 0.02% to about 1%, or about 0.05% to about 0.5% of the pharmaceutical composition by w/w, w/v or v/v.
[00122] In some embodiments, the amount of the compound in the pharmaceutical composition is about 0.00001 mg, 0.0001 mg, 0.001 mg, 0.005 mg, 0.01 mg, 0.05 mg, 0.1 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 4 mg, 8 mg, 10 mg, 12 mg, 14 mg, 16 mg, 18 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, 1 g, 1.1 g, 1.2 g, 1.3 g, 1.4 g, 1.5 g, 1.6 g, 1.7 g, 1.8 g, 1.9 g, 2 g, 2.5 g, 3 g, 3.5 g, 4 g, 4.5 g, 5 g, 6 g, 7 g, 8 g, 9 g, or 10 g.
Exemplary Modes of Administration
[00123] Administration of a pharmaceutical composition as described herein can be performed by any method that enables delivery of the compound to the site of action. The composition may be administered orally, parenterally, enterally, intraperitoneally, topically, transdermally, ophthalmically, intranasally, locally, non-orally, via spray, subcutaneously, intravenously, intratonsillary, intramuscularly, buccally, sublingually, rectally, intravaginally (e.g., via vaginal pessaries, e.g., using methods described in Capra et al. Journal of Pharmaceutics 2013, 386546, which is incorporated herein by reference in its entirety), intraarterially, by infusion, or intrathecally. In some embodiments, the composition is administered orally. In some cases, the oral administration may comprise administration of any of the oral dosage forms as described herein. In some cases, a composition described herein is
administered sublingually. In some cases, a composition described herein is administered transdermally, e.g., via transdermal patch. The effective amount of a compound administered will be dependent on the subject being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discretion of the prescribing physician.
Pharmaceutical compositions for oral administration
[00124] The pharmaceutical composition comprising an effective amount of a compound can be formulated for oral administration. In some embodiments, the pharmaceutical composition comprising an effective amount of a compound for oral administration is a solid pharmaceutical composition. In some embodiments, the solid pharmaceutical composition may be presented as discrete (e.g., unit) oral dosage forms. Non-limiting examples of discrete oral dosage forms include tablets, capsules, caplets, gelatin capsules, sustained release formulations, lozenges, thin films, lollipops, chewing gum. In some embodiments, the discrete oral dosage form is an orally disintegrating oral dosage form, such as, an orally disintegrating tablet.
[00125] In some embodiments, the pharmaceutical composition comprising an effective amount of a compound for oral administration is a liquid pharmaceutical composition. Nonlimiting examples of liquid compositions for oral administration include hydrophilic suspensions, emulsions, liquids, gels, syrups, slurries, solutions, elixirs, softgels, tinctures, and hydrogels. In some embodiments, solid or liquid compositions comprising an effective amount of a compound for oral administration comprise various sweetening or flavoring agents, or coloring agents. Examples of coloring agents include dyes suitable for food such as those known as F.D. & C. dyes and natural coloring agents such as grape skin extract, beet red powder, beta carotene, annato, carmine, turmeric, paprika, and so forth. Derivatives, analogues, and isomers of any of the above colored compound also may be used.
[00126] The choice of carrier will be determined, in part, by the particular compound, as well as by the particular method used to administer the compound. Accordingly, there are a variety of suitable formulations of the pharmaceutical composition of this disclosure. The following formulations for parenteral, subcutaneous, intravenous, intramuscular, intraarterial, intrathecal and interperitoneal administration are exemplary, and are in no way limiting. More
than one route can be used to administer the compounds, and in certain instances, a particular route can provide a more immediate and more effective response than another route.
Pharmaceutical compositions for injection or parenteral administration
[00127] Parenteral vehicles (for subcutaneous, intravenous, intraarterial, or intramuscular injection) include, for example, sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's and fixed oils. Formulations suitable for parenteral administration include, for example, aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
[00128] Intravenous vehicles include, for example, fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like. Examples are sterile liquids such as water and oils, with or without the addition of a surfactant and other pharmaceutically acceptable adjuvants. Non-limiting examples of liquid carriers (e.g., liquid carriers suitable for injectable solutions) include water, saline, aqueous dextrose and related sugar solutions, and glycols such as propylene glycols or polyethylene glycol. Suitable soaps for use in parenteral formulations include, for example, fatty alkali metal, ammonium, and triethanolamine salts, and suitable detergents include, for example, (a) cationic detergents such as, for example, dimethyl dialkyl ammonium halides, and alkyl pyridinium halides, (b) anionic detergents such as, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates, (c) nonionic detergents such as, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylenepolypropylene copolymers, (d) amphoteric detergents such as, for example, alkyl-P-aminopropionates, and 2-alkyl- imidazoline quaternary ammonium salts, and (e) mixtures thereof.
[00129] The parenteral formulations will typically contain from about 0.5% to about 25% by weight of the compounds in solution. Preservatives and buffers may be used. In order to minimize or eliminate irritation at the site of injection, such compositions may contain one or more nonionic surfactants, for example, having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulations will typically range from about 5% to about 15% by weight. Suitable surfactants include, for example, polyethylene
glycol sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.
[00130] The parenteral formulations can be presented in unit-dose or multi-dose sealed containers, such as ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets.
[00131] Injectable formulations are in accordance with this disclosure. The requirements for effective pharmaceutical carriers for injectable compositions are well-known to those of ordinary skill in the art (see, e.g., Pharmaceutics and Pharmacy Practice, J.B. Lippincott Company, Philadelphia, PA, Banker and Chalmers, eds., pages 238-250 (1982), and ASHP Handbook on Injectable Drugs, Trissei, 15th ed., pages 622-630 (2009)).
Other pharmaceutical compositions
[00132] Alternatively, the compounds of this disclosure can be modified into a depot form, such that the manner in which the compound is released into the body to which it is administered is controlled with respect to time and location within the body (see, for example, U.S. Patent No. 4,450,150). Depot forms of compounds can be, for example, an implantable composition comprising the compound and a porous or non-porous material, such as a polymer, wherein the compound is encapsulated by or diffused throughout the material and/or degradation of the non-porous material. The depot is then implanted into the desired location within the body and the compounds are released from the implant at a predetermined rate.
[00133] In some embodiments, the compounds of this disclosure provided herein can be controlled release compositions, i.e., compositions in which the one or more compounds are released over a period of time after administration. Controlled or sustained release compositions include formulation in lipophilic depots (e.g., fatty acids, waxes, oils). In another embodiment the composition is an immediate release composition, i.e., a composition in which all or substantially all of the compound is released immediately after administration.
[00134] In yet another embodiment, the compounds of this disclosure can be delivered in a controlled release system. For example, the agent may be administered using intravenous infusion, an implantable osmotic pump, a transdermal patch, or other modes of administration.
In some embodiments, a pump may be used. In some embodiments, polymeric materials can be used. In yet another embodiment, a controlled release system can be placed in proximity to the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Design of Controlled Release Drug Delivery Systems, Xiaoling Li and Bhaskara R. Jasti eds. (McGraw-Hill, 2006)).
[00135] In some embodiments, the pharmaceutical compositions of this disclosure comprise the compounds of this disclosure, for example, the compounds disclosed herein, and/or their salts, solvates or stereoisomers thereof, and optionally, one or more additional therapeutic agents, such as, for example, 5-HT receptor inhibitors, antibiotics, anti-inflammatory, immunomodulators, together with a pharmaceutically acceptable carrier.
[00136] Examples of antibiotic agents suitable for use in pharmaceutical composition comprising the compounds heretofore described above and one or more antibiotic agents include, for example, quinolone antibiotics, such as levofloxacin, ciprofloxacin, ibafloxacin, pradofloxacin, rosoxacin, and sarafloxacin. Other suitable antibiotics are trimethoprimsulfamethoxazole mixtures such as Bactrim®. Alternatives include rifaximin and azithromycin. Dosages vary with the weight and age of the subject to be treated. Typically, quinolone antibiotics and trimethoprim-sulfamethoxazole mixtures are given at dosages between 250 and 500 mg daily. For trimethoprim-sulfamethoxazole, the dosages are generally between about 5 mg/kg and 25 mg/kg. For rifaximin the dosage ranges from 100 mg to about 500 mg (e.g., 200 mg). Azithromycin is typically administered at 250-500 mg/day. The dosages required are well within the knowledge of those of ordinary skill in the art.
[00137] General considerations
[00138] For purposes of this disclosure, the amount or dose of the compounds, salts, solvates, or stereoisomers of any one the compounds of Formula (I), as set forth above, administered should be sufficient to effect, e.g., a therapeutic or prophylactic response, in the subject over a reasonable time frame. The dose will be determined by the efficacy of the particular compound and the condition of a human, as well as the body weight of a human to be treated.
[00139] The dose of the compounds, salts, solvates, or stereoisomers of any one the compounds as set forth above, of this disclosure also will be determined by the existence, nature
and extent of any adverse side effects that might accompany the administration of a particular compound.
[00140] Typically, an attending physician will decide the dosage of the compound with which to treat each individual patient, taking into consideration a variety of factors, such as age, body weight, general health, diet, sex, compound to be administered, route of administration, and the severity of the condition being treated. By way of example, and not intending to limit this disclosure, the dose of the compound can be about 0.001 to about 1000 mg/kg body weight of the subject being treated/day, from about 0.01 to about 100 mg/kg body weight/day, about 0.1 mg to about 10 mg/kg body weight/day. The several aspects of this disclosure, described above, are shown in the following examples.
EXAMPLES
[00141] Example 1: 12-Chloro-9-(2-fluorophenyl)-2,3,8-triazatricyclo[8.4.0.02,6]tetradeca- l(10),3,5,8,l l,13-hexaene-5-carboxylic acid (Compound 102)
[00142] Step 1: Ethyl l-(4-chlorophenyl)-5-methyl-lH-pyrazole-4-carboxylate
[00143] Ethyl acetoacetate (8.06 mL, 1 eq.) was refluxed with A'A -di methyl form am ide dimethyl acetal (10.19 mL, 1 eq.) for 1 hour. After cooling to room temperature the excess DMFDMA was distilled off under reduced pressure. The obtained residue was added to the solution of 4-chlorophenylhydrazine hydrochloride (8 g, 1 eq.) and DIPEA (8.56 mL, 1.1 eq.) in MeOH (100 mL). The resulting solution was refluxed for 3 hours. After cooling to room temperature the solvent was evaporated under reduced pressure. Obtained residue was dissolved in DCM (100 mL), washed with water (50 mL), dried over anhydrous magnesium sulfate and evaporated in vacuo. Product was purified using flash chromatography on silica, eluting with ethyl acetate. 7.38 g was obtained as a dark oil (62%). ESI(+): 265.05 (+H+).
[00144] Step 2: Ethyl l-[4-chloro-2-(2-fluorobenzoyl)phenyl]-5-methyl-lH-pyrazole-4- carb oxy late
[00145] Ethyl l-(4-chlorophenyl)-5-methyl-lH-pyrazole-4-carboxylate (4 g, 1 eq.) was dissolved in l,2di chloroethane (20 mL). Palladium trifluoroacetate (0.5 g, 0.1 eq.) was added and the mixture was stirred for 40 minutes, until the solution became clear. Then, tert-butyl hydroperoxide solution (5-6 M in decane, 7.56 mL, 2.5 eq.) and 2-fluorobenzaldehyde (3.18 mL, 2 eq.) were added and the mixture was heated at 90 °C for 20 hours. After cooling to room temperature the reaction mixture was washed with water (20 mL), brine (2 mL), dried over anhydrous magnesium sulfate and evaporated in vacuo. The crude product was purified by silica gel chromatography, eluting with 80% hexane : 20% ethyl acetate. 3.4 g of a yellow solid was obtained (58%). ESI(+): 386.95 (+H+).
[00146] Step 3: Ethyl 5-(bromomethyl)-l-[4-chloro-2-(2-fluorobenzoyl)phenyl]-lH- py razol e-4-carb oxy 1 ate
[00147] Ethyl l-[4-chloro-2-(2-fluorobenzoyl)phenyl]-5-methyl-lH-pyrazole-4- carboxylate (1 g, 1 eq.) and A-bromosuccinimide (506 mg, 1.1 eq.) were dissolved in 1,2- di chloroethane (15 mL) and refluxed for30 minutes. Then, dibenzoyl peroxide (125 mg, 0.15 eq.) was added in one portion and the reaction mixture was refluxed for 6 hours. After cooling to room temperature the solution was concentrated with silica gel (10 g), which was subjected to flash chromatography on silica, eluting with a gradient hexane:ethyl acetate 0%-20%. 483 mg of a white solid was obtained (40%). ESI(+): 464.85 (+H+).
[00148] Step 4: Ethyl 12-chloro-9-(2-fluorophenyl)-2,3,8-triazatricyclo[8.4.0.02,6] tetradeca- 1(10), 3, 5, 8, 11, 13 -hexaene- 5 -carb oxy late
[00149] Ethyl 5 -(bromomethyl)- 1 - [4-chloro-2-(2-fluorobenzoyl)phenyl] - 1 H-pyrazole-4- carboxylate (480 mg, 1 eq.), ammonium acetate (350 mg, 3 eq.) and urotropine (430 mg, 3 eq.) were dissolved in isopropanol (10 mL) and heated to reflux for 2 hours. After cooling to room temperature the solvent was evaporated and the residue was suspended in water (50 mL). The suspension was extracted with ethyl acetate (3x 30 mL). Combined organic extracts were washed with brine (5 mL), dried over anhydrous MgSCU and evaporated to dryness under reduced pressure. The product was used in the next step without purification. 391 mg of a solid was obtained (98%). ESI(+): 383.95 (+H+).
[00150] Step 5: 12-Chloro-9-(2-fluorophenyl)-2,3,8-triazatricyclo[8.4.0.02,6]tetradeca- 1(10), 3, 5, 8,1 l,13-hexaene-5-carboxylic acid
[00151] Ethyl 12-chloro-9-(2-fluorophenyl)-2,3,8-triazatricyclo[8.4.0.02,6]tetradeca- l(10),3,5,8,l l,13-hexaene-5-carboxylate (240 mg, 1 eq.) was dissolved in a mixture of THF and water 1 : 1 (6 mL). Lithium hydroxide monohydrate (77 mg, 3 eq.) was added in one portion and the mixture was stirred at 50 °C overnight. Then, THF was evaporated and the resulting solution was acidified with a dilute hydrochloric acid. Resulting precipitate was collected, washed with water (20 mL) and dried under reduced pressure. Solid was triturated with ethyl acetate. 130 mg of a white solid was obtained (59%). ESI(+): 356.00 (+H+). ’H NMR (400 MHz, DMSO-tA) 6 12.94 (s, 1H), 8.20 (s, 1H), 8.00 (d, J= 8.8 Hz, 1H), 7.85 (dd, J= 8.8, 2.4 Hz, 1H), 7.67 - 7.50 (m, 2H), 7.39 - 7.27 (m, 2H), 7.27 - 7.17 (m, 1H), 5.01 (s, 2H).
[00153] Example 3: 12-Chloro-9-(2-fluorophenyl)-2,3,4,8-tetraazatricyclo[8.4.0.02,6] tetradeca-l(10),3,5,8,l l,13-hexaene-5-carboxylic acid (Compound 101)
[00154] Step 1: (2-Azido-5-chlorophenyl)(2-fluorophenyl)methanone
[00155] 2- Amino-5-chl oro-2’ fluorobenzophenone (4 g, 1 eq.) and p-toluenesulfonic acid monohydrate were placed in a round bottom flask and dissolved in acetonitrile (160 mL). Then, a solution of sodium nitrite (2.21 g, 2 eq.) and sodium azide (2.6 g, 2.5 eq.) in water (96 mL) was added drop-wise. The solution was stirred at room temperature for 2 hours. The reaction was quenched by addition of a 10% sodium sulfite solution (50 mL). Acetonitrile was evaporated under reduced pressure and the residue was extracted with DCM (3x 70 mL). Combined organic extracts were washed with brine (10 mL), dried over anhydrous MgSCU and evaporated to dryness under reduced pressure. Product was purified with flash chromatography on silica, eluting with a gradient hexane : ethyl acetate 100%-70%. 3.7 g of a white solid was obtained (83%). ESI(+) product decomposes upon ionization.
[00156] Step 2: Methyl l-[4-chloro-2-(2-fluorobenzoyl)phenyl]-5-(hydroxymethyl)-lH- l,2,3-triazole-4-carboxylate.
[00157] (2-Azido-5-chlorophenyl)(2-fluorophenyl)methanone (600 mg, 1 eq.) and methyl 4-hydroxybut-2-ynoate (298 mg, 1.2 eq.) were dissolved in anhydrous toluene (32 mL) and [Cp*RuCl]4 (118 mg, 0.05 eq.) was added in one portion. The reaction was stirred at room temperature overnight. The solution was filtered through a silica pad, which was washed with ethyl acetate (100 mL). Combined organic filtrates were evaporated under reduced pressure. 800 mg of a yellow solid was obtained (99%). Product was used in the next step without purification. ESI(+): 390 (+H+).
[00158] Step 3: Methyl l-[4-chloro-2-(2-fluorobenzoyl)phenyl]-5-[(methanesulfonyl oxy)methyl]- 1H- 1 ,2,3 -triazole-4-carboxylate
[00159] Methyl l-[4-chloro-2-(2-fluorobenzoyl)phenyl]-5-(hydroxymethyl)-lH-l,2,3- triazole-4-carboxylate (200 mg, 1 eq.) and DIPEA (0.197 mL, 2.2 eq.) were dissolved in DCM
(7.7 mL) and cooled to 0 °C with an ice bath. Then, methanesulfonyl chloride (0.079 mL, 2 eq.) was added dropwise. The solution was allowed to warm to room temperature and was stirred for 12 hours. The solution was diluted with DCM (50 mL) washed with water (60 mL), brine (10 mL), dried over anhydrous magnesium sulfate and evaporated in vacuo. Product was used in the next step without purification. 0.24 g of a light yellow solid was obtained (99%). ESI(+): 467.65 (+H+).
[00160] Step 4: Methyl 12-chloro-9-(2-fluorophenyl)-2,3,4,8-tetraazatricyclo[8.4.0.02,6] tetradeca- 1(10), 3, 5, 8, 11, 13 -hexaene- 5 -carb oxy late
[00161] Methyl l-[4-chloro-2-(2-fluorobenzoyl)phenyl]-5-[(methanesulfonyloxy)methyl]- lH-l,2,3-triazole-4-carboxylate (430 mg, 1 eq.) was dissolved in isopropanol (18 mL). Ammonium acetate (415 mg, 3 eq.) and urotropine (515 mg, 3 eq.) were added and the reaction mixture was heated to reflux for 4 hours. After cooling to room temperature the solvent was evaporated and the residue was suspended in water (100 mL). The suspension was extracted with ethyl acetate (3x 40 mL). Combined organic extracts were washed with brine (10 mL), dried over anhydrous MgSCh and evaporated to dryness under reduced pressure. The product was purified with flash chromatography on silica eluting with a gradient DCM : MeOH 0%- 10%. 320 mg of a white solid was obtained (93%). ESI(+): 370.90 (+H+).
[00162] Step 5: 12-Chloro-9-(2-fluorophenyl)-2,3,4,8-tetraazatricyclo[8.4.0.02,6]tetradeca- 1(10), 3, 5, 8,1 l,13-hexaene-5-carboxylic acid
[00163] Methyl 12-chloro-9-(2-fluorophenyl)-2, 3 ,4, 8-tetraazatricy clo[8.4.0.02,6]tetradeca- l(10),3,5,8,l l,13-hexaene-5-carboxylate (320 mg, 1 eq.) was dissolved in a mixture of THF and water 1 :1 (8.6 mL). Lithium hydroxide monohydrate (109 mg, 3 eq.) was added in one portion and the mixture was stirred at room temperature overnight. Then, THF was evaporated and the resulting solution was acidified with a dilute hydrochloric acid. Resulting precipitate was collected, washed with water (50 mL) and dried under reduced pressure. 230 mg of a white solid was obtained (74%). ESI(+): 356.90 (+H+). ’H NMR (400 MHz, DMSO-t/e) 6 12.63 (s, 1H), 8.39 (d, J= 5.4 Hz, 1H), 8.05 (dd, J= 10.6, 2.3 Hz, 1H), 7.67 - 7.52 (m, 2H), 7.34 (td, J = 7.6, 1.1 Hz, 1H), 7.30 - 7.12 (m, 2H), 5.20 (d, J= 12.8 Hz, 1H), 4.34 (d, J= 12.8 Hz, 1H).
[00164] Example 4: 8-chloro-6-(2-fluorophenyl)-4H-benzo[f]imidazo[l,5-a][l,4]diazepine -3-carboxylic acid (Compound 104)
[00165] Step 1: ethyl 8-chloro-6-(2-fluorophenyl)-4H-imidazo[l,5-a][l,4]benzodiazepine- 3 -carboxylate
[00166] To a stirring solution of 7-Chloro-5-(2-fluorophenyl)-lH-benzo-[e][l,4]diazepin- 2(3H)-one (1 g, 3.5 mmol) in THF (10 mL) and DMF (5 mL) at 0 °C, potassium t-butoxide (0.5g, 4.5 mmol) was added. The solution was stirred at 0 °C for 30 min. 1- [chloro(ethoxy)phosphoryl]oxyethane (0.7 mL, 4.5 mmol) was added. The solution was then stirred at room temperature for three hours. The solution was cooled 0 °C, ethyl 2- isocy anoacetate (0.6 g, 4.9 mmol) was added. The solution was stirred at 0 °C for 30 min. Then the solution was cooled to -78 °C, potassium t-butoxide (0.5 g, 4.5 mmol) was added. The solution was allowed to return to room temperature and stirred at room temperature overnight. Ethyl acetate (200 ml) was added. The solution was extracted with water (3 X 50 ml), brine (50 ml), dried over sodium sulfate. The solution was filtered and concentrated. The residue was purified by automated flash chromatography, eluting with a 20-100% gradient of ethyl acetate in heptane to give ethyl 8-chloro-6-(2-fluorophenyl)-4H-imidazo[l,5-a][l,4]benzodiazepine- 3-carboxylate (1.1 g, 3.0 mmol, 86% yield) as slightly colored oil. XH NMR (400 MHz, chloroform-d3) 6 ppm 1.39 - 1.55 (m, 3 H) 4.02 - 4.22 (m, 2 H) 4.44 (br. s., 2 H) 6.14 (br. s., 1 H) 7.00 - 7.12 (m, 1 H) 7.23 - 7.40 (m, 3 H) 7.47 (tdd, J=7.77, 7.77, 5.31, 1.89 Hz, 1 H) 7.54 - 7.60 (m, 1 H) 7.61 - 7.76 (m, 2 H) 7.95 - 8.03 (m, 1 H).
[00167] Step 2: 8-chloro-6-(2-fhiorophenyl)-4H-benzo[f]imidazo[l,5-a][l,4]diazepine-3- carboxylic acid
[00168] To a stirring solution of ethyl 8-chloro-6-(2-fluorophenyl)-4H-imidazo[l,5- a][l,4]benzodiazepine-3-carboxylate (829 mg, 2.2 mmol) in THF (5 mL), IN sodium hydroxide solution (3.2 mL, 3.2 mmol) was added. The solution was stirred at room temperature overnight. The solution was concentrated. The residue was purified by preparative HPLC, eluting with a gradient of water/acetonitrile (5-100%) to give 8-chloro-6-(2-
fluorophenyl)-4H-imidazo[l,5-a][l,4]benzodiazepine-3-carboxylic acid (142 mg, 0.4 mmol, 18% yield) as a white solid. ESI(+): 356.0. ’H NMR (400 MHz, DMSO-d6) d ppm 4.17 (br. s., 1 H) 5.83 (br. s., 1 H) 7.23 (t, J=9.47 Hz, 1 H) 7.27 - 7.38 (m, 2 H) 7.50 - 7.67 (m, 2 H) 7.83 - 7.90 (m, 1 H) 7.92 - 8.00 (m, 1 H) 8.44 (s, 1 H) 12.76 (br. s., 1 H).
[00169] Example Bl
[00170] Modulatory effects of the compounds of this disclosure were investigated using cells stably transfected with GABA-activated channels of the GAB AA (0.36272) subtype together with submaximal GABA concentrations. Expression of GABA receptor were induced by adding Dexamethasone to the cells for 24 to 48h before experimentation. In general, cells were passaged at a confluence of about 80 to 90%. For electrophysiological measurements cells were harvested at a confluence of about 80 to 90% from sterile culture flasks containing culture complete medium. Cells were transferred as suspension in PBS to the QPatch 16X or QPatch HTX system to the centrifuge / washer directly. Cells were incubated at 37°C in a humidified atmosphere with 5% CO2 (rel. humidity about 95%). The cells were continuously maintained in and passaged in sterile culture flasks containing a 1 : 1 mixture of Dulbecco’s modified eagle medium and nutrient mixture D-MEM/F-12 (lx, liquid, with L-Glutamine), supplemented with 10% foetal bovine serum and 1.0% Penicillin/Streptomycin solution and neomycin. The lx bath solution was made at least every 5 days out of a sterile lOx bath solution, which had been prepared prior to the experimental start of the present study and stored at 1°C to 9°C. The final bath solution included Sodium Chloride 137 mM, Potassium Chloride 4 mM, Calcium Chloride 1.8 mM , Magnesium Chloride 1 mM, HEPES 10 mM, D-Glucose 10 mM, pH (NaOH) 7.4. The lx intracellular solution was thawed every day and includes Potassium Chloride 130 mM, Magnesium Chloride 1 mM, Mg-ATP 5 mM, HEPES 10 mM, EGTA 5 Mm, pH (KOH) 7.2. Automated patch-clamping: Cells were transferred as suspension in serum-free medium to the QPatch HTX system and kept in the cell storage tank during experiments. All solutions applied to cells including the intracellular solution were maintained at room temperature (19°C to 30°C). After formation of a Gigaohm seal between the patch electrodes and transfected individual Ltk cells were ruptured to assure electrical access to the cell interior (whole-cell patch-configuration). Inward currents were measured upon application of 2.0 pM GABA to patch-clamped cells for 4 s. During the entire experiment the cells were voltage-clamped at a
holding potential of -80 mV. For the analysis of test items, GAB AA receptors were stimulated by 2.0 pM GABA and test item combinations described below. Thirty-second prewash steps with test items was performed in between two agonist applications. The dose-response curve was fit with a sigmoidal three parameter equation current=Emax/l+10A((LogEC50- X)*ET) where X is the compound concentration, Emax the upper asymptote, ECso the concentration of test item at half maximal effect, and H is the Hill coefficient. SigmaPlot 11.0 was used for construction of curve. Data for exemplary compounds are provided below, in Table Bl
[00172] Keys:
For ECso: + represents that ECso> l 00 nM; ++ represents that EC50 is 50-100 nM; +++ represents that ECso < 50nM;
For Emax: + represents that Emax <50%; ++ represents that Emax is 50-100%; +++ represents that Emax >100%.
[00173] Example B2: Effects of the compounds and methods of this disclosure on whole gut transit time.
[00174] Dose responses of the effect of Formula (I) compounds on the whole gut transit time (WGTT) are examined. A compound of Formula (I) (0, 1, 3 and 10 mg/kg) in 50% propylene glycol is administrated by gavage (5 ml/kg), followed by gavage of 0.2 ml carmine red solution (6% carmine red in 0.5% methylcellulose) into C57B/6 mice. Mice are then placed in a white cardboard box and the time is recorded as time 0. The color of stool is observed every 10 min until the red dye appears in stool. The time that first red stool appears is recorded as the ending time. The difference between the ending time and time 0 is used to present WGTT (min).
[00175] Example B3: Effects on distal colon transit time.
[00176] The time course of a compound of Formula (I) on distal colon transit time (DCTT) in C57B/6 mice is examined to assess the colon motility. DCTT is performed by gently pushing
a 2 mm glass bead into rectal 2 cm and then placing the mouse into a white box (time 0). The time that the glass bead is released from rectal is presented as DCTT (min). Mice are gavaged with 0 or 3 mg/kg of a compound of Formula (I) and DTCC is conducted at 30, 60, 90 and 120 min after the administration of a compound of Formula (I).
[00177] Example B4 Effects on stool composition.
[00178] After gavage of a compound of Formula (I) (3 and 10 mg/kg), stools are collected immediately after expulsion for 3 hours. The wet stools are weighted as total stool weight followed by dry at 65°C for 24 hours and weight as dry stool weight. The percent of water content in the stool is calculated by (total stool weight- dry stool weight)/ total stool weight x 100.
[0100] Example B5: Pain sensitivity in IBS mouse model.
[0101] IBS visceral pain model, induced by neonatal rectal irritation, is used. Colonic pain sensitivity to graded colorectal balloon distension (CRD, 15, 30, 50 and 70mmHg) is determined by visceromotor response (VMR) measured by electromyography of external oblique muscle. IBS mice show a significant increase in pain sensitivity relative to control mice. IBS mice are treated with a compound of Formula (I) (10 mg/kg). Hyperalgesia in IBS mice is then examined.
[0102] Example B6: Measurement of brain and plasma levels.
[0103] A compound of Formula (I) is administered to 5 mice at a dose of lOmg/kg as a solution in 50% propylene glycol by oral gavage (5 ml/kg). After 30 minutes, mice are sacrificed and plasma and brain are harvested. The concentration of the Formula (I) compound in plasma and brain are measured by LC/MS. Average plasma concentrations and brain concentration are examined.
[0104] Example B7: Measurement of GABA-A binding.
[0105] Potency at the GABA-A receptor is measured by [3H]flunitrazepam binding to rat cerebral cortex tissue homogenate as described in Speth, R.C, Wastek, G.J., Johnson, P.C., Yamamura, H.I. “Benzodiazepine binding in human brain: Characterization using [3H] flunitrazepam” Life Sciences 1978, 22, 859-866 (incorporated herein by reference in its entirety)and performed at CEREP (catalog number 0028).
[00179] The following references cited above are incorporate herein by reference in their entirety:
[00180] 1. Everhart JE. The burden of digestive diseases in the United States. US
Government Printing Office (NIH Publication No. 09-6443), 2008.
[00181] 2 Sullivan MA, Cohen S, Snape WJ, Jr. Colonic myoelectrical activity in irritable- bowel syndrome. Effect of eating and anticholinergics. N Engl J Med 1978;298:878-83.
[00182] 3. Gershon MD. Serotonin and its implication for the management of irritable bowel syndrome. Rev Gastroenterol Disord 2003;3 Suppl 2:S25-34.
[00183] 4. Pasricha PJ. Desperately seeking serotonin. A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders. Gastroenterology 2007;132:2287-90.
[00184] 5. Fargeas MJ, Fioramonti J, Bueno L. Central and peripheral action of GABAA and GAB AB agonists on small intestine motility in rats. European Journal of Pharmacology 1988;150: 163-169.
[00185] 6. Grider JR. Interplay of somatostatin, opioid, and GABA neurons in the regulation of the peristaltic reflex. American Journal of Physiology - Gastrointestinal and Liver Physiology 1994;267:G696-G701.
[00186] 7 Kerr DIB, Ong J. GABA and GABA-receptors in the enteric nervous system.
Neuropharmacology 1984;23 : 835 -836.
[00187] 8. Krantis A. GABA in the mammalian enteric nervous system. News in
Physiological Sciences 2000;15:284-290.
[00188] 9. Krantis A, Costa M, Furness JB, Orbach J. y-Aminobutyric acid stimulates intrinsic inhibitory and excitatory nerves in the guinea-pig intestine. European Journal of Pharmacology 1980;67:461-466.
[00189] 10. Ong J, Kerr DIB. Evidence for a physiological role of GABA in the control of guinea-pig intestinal motility. Neuroscience Letters 1984;50:339-343.
[00190] 11. Reis HJ, Berghe PV, Romano-Silva MA, Smith TK. GABA-induced calcium signaling in cultured enteric neurons is reinforced by activation of cholinergic pathways. Neuroscience 2006;139:485-494.
[00191] 12. Williamson S, Faulkner- Jones BE, Cram DS, Furness JB, Harrison LC.
Transcription and translation of two glutamate decarboxylase genes in the ileum of rat, mouse and guinea pig. Journal of the Autonomic Nervous System 1995;55: 18-28.
[00192] 13. Williamson S, Pompolo S, Furness JB. GABA and nitric oxide synthase immunoreactivities are colocalized in a subset of inhibitory motor neurons of the guinea-pig small intestine. Cell and Tissue Research 1996;284:29-37.
[00193] 14. Salari P, Abdollahi M. Systematic review of modulators of benzodiazepine receptors in irritable bowel syndrome: is there hope? World J Gastroenterol 2011; 17:4251-7.
[00194] 15. Ritchie JA, Truelove SC. Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk. Br Med J 1979;1 :376-8.
[00195] 16. Pace F, Maurano A, Ciacci C, Savarino V, Attili A, laquinto G, Magni E, Porro
GB. Octatropine methyl bromide and diazepam combination (Valpinax) in patients with irritable bowel syndrome: a multicentre, randomized, placebo-controlled trial. Eur Rev Med Pharmacol Sci 2010;14: 155-62.
[00196] 17. Talley NJ. Evaluation of drug treatment in irritable bowel syndrome. British
Journal of Clinical Pharmacology 2003;56:362-369.
[00197] 18. Horvath K, Andrasi F, Berzsenyi P, Patfalusi M, Patthy M, Szabo G, Sebestyen
L, Bagdy E, Korosi J, Botka P, Hamori T, Lang T. A New Psychoactive 5h-2,3-Benzodiazepine with a Unique Spectrum of Activity. Arzneimittel-Forschung/Drug Research 1989;39-2:894- 899.
[00198] 19. Mennini T, Abbiati A, Caccia S, Cotecchia S, Gomez A, Garattini S. Brain
Levels of Tofizopam in the Rat and Relationship with Benzodiazepine Receptors. Naunyn- Schmiedebergs Archives of Pharmacology 1982;321 : 112-115.
[00199] 20. Bagal SK, Bungay PJ. Minimizing Drug Exposure in the CNS while
Maintaining Good Oral Absorption. Acs Medicinal Chemistry Letters 2012;3:948-950.
[00200] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
[00201] The use of the terms “a” and “an” and “the” and similar referents in the context of describing this disclosure (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are
to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate this disclosure and does not pose a limitation on the scope of this disclosure unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of this disclosure. [00202] Preferred embodiments of this disclosure are described herein, including the best mode known to the inventors for carrying out this disclosure. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for this disclosure to be practiced otherwise than as specifically described herein. Accordingly, this disclosure includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by this disclosure unless otherwise indicated herein or otherwise clearly contradicted by context.
Claims
1. A compound of Formula (I):
Formula (I) or a pharmaceutically acceptable salt thereof, wherein: each of A1 and A2 is independently selected from the group consisting of N and CR3, provided that one of A1 and A2 is N;
Rla, Rlb, Rlc, and Rld are each independently selected from the group consisting of: H, halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, cyano, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 thioalkoxy, C1-6 halothioalkoxy, S(O)2(Ci-6 alkyl), S(=O)(=NH)C I-6 alkyl, Si(Ci-6 alkyl)3, C3-6 cycloalkyl, Ce-io aryl, NR6R7, C(O)R6, and C(O)NR6R7, wherein the C3-6 cycloalkyl and Ce-io aryl are each optionally substituted with from 1- 4 substituents each independently selected from the group consisting of: halo, cyano, C1-6 alkyl, and C1-6 haloalkyl; each R2 is independently selected from the group consisting of: halo, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, NO2, cyano, C1-6 alkoxy, C1-6 haloalkoxy, SO2(Ci-6 alkyl), S(=O)(=NH)C I-6 alkyl, C3-6 cycloalkyl, NR6R7, C(O)R6, and C(O)NR6R7; m is 0, 1, 2, or 3;
X is selected from the group consisting of: -CO2H, -CH(RX)CO2H, -C(O)Y, - CH(RX)C(O)Y, -S(O)2Y, -CH(RX)S(O)2Y, -(C1-3 alkylene)-N+(Ci-3 alkyl)3, -P(=O)(OH)2, -
XA and XB are independently O, S, N(H), or N(CI-3 alkyl);
Rx is selected from the group consisting of: H, Ci-6 alkyl, -OH, and -NR6R7;
Y is selected from the group consisting of:
(i) -NR6R7;
(ii) -NR8-CH2CH2O-(-CH2CH2O-)n-Y4, wherein n is an integer between 0 and 20; and
(iii) -NR8-Y2-Y3;
Y2 is C2-6 alkylene;
Y3 is selected from the group consisting of: -NR6R7; -NR9S(O)2NR9R10; -S(O)2R6; - S(=O)R6(=NR8); and -P(=O)(Ci-3 alkyl)2;
Y4 is H or C1-6 alkyl;
R3 is selected from the group consisting of:
H; halo; cyano; C1-6 alkyl; C1-6 haloalkyl; C2-6 alkenyl; C2-6 alkynyl; C1-6 alkoxy; C1-6 haloalkoxy; -NR6R7; -C(O)NR6R7; -CH2NR6R7; C3-6 cycloalkyl; Ce-io aryl; and heteroaryl including from 5-6 ring atoms, wherein from 1-4 ring atoms are heteroatoms each independently selected from the group consisting of: N, N(R8), O, and S;
R4 and R5 are independently selected from the group consisting of: H, C1-6 alkyl, -OH, and -NR6R7; or
R4 and R5 taken together with the carbon atom to which each is attached forms a C3-6 cycloalkyl;
each occurrence of R6 and R7 is independently selected from the group consisting of: H, Ci-6 alkyl, Ci-6 haloalkyl, C3-6 cycloalkyl, phenyl, -(Ci-4 alkylene)-phenyl, C(=O)R9, C(=O)OR9, and C(=O)NR9R10; or a pair of R6 and R7 on the same nitrogen atom, taken together with said nitrogen atom connecting them, forms a saturated, partially unsaturated, or aromatic ring including 4-8 ring atoms, wherein from 0-2 ring atoms (in addition to the nitrogen atom connecting R6 and R7) are ring heteroatoms each independently selected from the group consisting of: N, N(R8), O, and S; each occurrence of R8 is independently selected from the group consisting of: H, Ci-6 alkyl, -C(=O)R9, -C(=O)OR9, and -C(=O)NR9R10; each occurrence of R9 and R10 is H or Ci-6 alkyl; and
2. The compound of claim 1, wherein one of A1 and A2 is N, and the other of A1 and A2 is CR3.
3. The compound of claim 1 or 2, wherein A1 is N, and A2 is CR3.
4. The compound of claim 1 or 2, wherein A2 is N, and A1 is CR3.
5. The compound of claim 1 or 2, wherein A1 and A2 are both N.
6. The compound of any one of claims 1-5, wherein from 1 of Rla, Rlb, Rlc, and Rld is an independently selected substituent other than H.
7. The compound of any one of claims 1-6, wherein one of Rla, Rlb, Rlc, and Rld is selected from the group consisting of: Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 thioalkoxy, C1-6 halothioalkoxy, and C3-6 cycloalkyl; and the other three of Rla, Rlb, Rlc, and Rld are H.
8. The compound of any one of claims 1-7, wherein one of Rla, Rlb, Rlc, and Rld is C1-6 alkyl; and the other three of Rla, Rlb, Rlc, and Rld are H.
9. The compound of any one of claims 1-6, wherein one of Rla, Rlb, Rlc, and Rld is selected from the group consisting of: halo, cyano, S(O)2(Ci-6 alkyl), S(=O)(=NH)CI-6 alkyl, NR6R7, C(O)R6, and C(O)NR6R7; and the other three of Rla, Rlb, Rlc, and Rld are H.
10. The compound of any one of claims 1-6 and 9, wherein one of Rla, Rlb, Rlc, and Rld is halo; and the other three of Rla, Rlb, Rlc, and Rld are H.
11. The compound of any one of claims 1-6, wherein Rlc is selected from the group consisting of: C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 thioalkoxy, C1-6 halothioalkoxy, and C3-6 cycloalkyl.
12. The compound of any one of claims 1-6 and 11, wherein Rlc is C1-6 alkyl.
13. The compound of any one of claims 1-6, wherein Rlc is selected from the group consisting of: halo, cyano, S(O)2(Ci-6 alkyl), S(=O)(=NH)CI-6 alkyl, NR6R7, C(O)R6, and C(O)NR6R7.
14. The compound of any one of claims 1-13, wherein m is 1 or 2.
15. The compound of any one of claims 1-14, wherein m is 1.
17. The compound of claim 16, wherein ml is 1.
18. The compound of any one of claims 1-17, wherein each R2 is independently selected from the group consisting of: halo, Ci-6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, NO2, cyano, C1-6 alkoxy, C1-6 haloalkoxy, SO2(Ci-6 alkyl), and C3-6 cycloalkyl.
19. The compound of any one of claims 1-18, wherein each R2 is independently selected from the group consisting of: halo, C1-6 alkyl, C1-6 haloalkyl, cyano, C1-6 alkoxy, and C1-6 haloalkoxy.
20. The compound of any one of claims 1-19, wherein each R2 is an independently selected halo, optionally -F, -Cl, or -Br.
21. The compound of any one of claims 1-20, wherein each of R4 and R5 is H.
22. The compound of any one of claims 1-20, wherein one of R4 and R5 is Ci-6 alkyl (e.g., CH3); and the other of R4 and R5 is H.
23. The compound of any one of claims 1-22, wherein X is -CO2H or - CH(RX)CO2H.
24. The compound of any one of claims 1-23, wherein X is -CO2H.
25. The compound of any one of claims 1-24, wherein R3 is H.
26. The compound of claim 1, wherein:
• one of Rla, Rlb, Rlc, and Rld is C1-6 alkyl, cyano, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 thioalkoxy, C1-6 halothioalkoxy, or halo (e.g., Br or -Cl); optionally Rlc is C1-6 alkyl, cyano, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 thioalkoxy, C1-6 halothioalkoxy, or halo (e.g., Br or -Cl);
• the other three of Rla, Rlb, Rlc, and Rld are H;
• m is 1 or 2 (e.g., 1);
• each R2 is an independently selected halo, such as -F, -Cl, or -Br; and
• A1 is N, and A2 is CR3; or A2 is N, and A1 is CR3; or A1 is N, and A2 is N.
27. The compound of claim 1 or 26, wherein:
• one of Rla, Rlb, Rlc, and Rld is C1-6 alkyl or halo (e.g., Br or -Cl); optionally Rlc is C1-6 alkyl or halo (e.g., Br or -Cl);
• the other three of Rla, Rlb, Rlc, and Rld are H;
• m is 1 or 2 (e.g., 1);
• each R2 is an independently selected halo, such as -F, -Cl, or -Br; and
• A1 is N, and A2 is CR3; or A2 is N, and A1 is CR3; or A1 is N, and A2 is
N.
28. The compound of claim 26 or 27, wherein one of Rla, Rlb, Rlc, and Rld is C1-6 alkyl, optionally Rlc is C1-6 alkyl.
29. The compound of claim 26 or 27, wherein one of Rla, Rlb, Rlc, and Rld is halo (e.g., Br or -Cl), optionally Rlc is halo (e.g., Br or -Cl).
30. The compound of any one of claims 26-29, wherein m is 1.
31. The compound of any one of claims 26-30, wherein R3 is H.
32. The compound of any one of claims 26-31, wherein R4 and R5 are each H.
33. The compound of any one of claims 26-31, wherein one of R4 and R5 is Ci-6 alkyl (e.g., CH3); and the other of R4 and R5 is H.
34. The compound of any one of claims 26-33, wherein X is -CO2H or -CH(RX)CO2H.
35. The compound of any one of claims 26-34, wherein X is -CO2H.
36. The compound of any one of claims 1-35, wherein Z is a lone pair of electrons.
38. The compound of claim 1, wherein the compound is selected from the group consisting of the compounds in Table Cl, or a pharmaceutically acceptable salt thereof.
39. A pharmaceutical composition comprising a compound of any one of claims 1- 38 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
40. A method of positively modulating GABA-A receptors in tissues and organs outside the brain and central nervous system in a subject in need thereof, the method comprising
administering to the subject a therapeutically effective amount of a compound as claimed in any one of claims 1-38 or a pharmaceutical composition as claimed in claim 39.
41. A method of treating or preventing visceral pain in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound as claimed in any one of claims 1-38 or a pharmaceutical composition as claimed in claim 39.
42. A method of modulating gut motility in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound as claimed in any one of claims 1-38 or a pharmaceutical composition as claimed in claim 39.
43. A method of treating irritable bowel syndrome in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound as claimed in any one of claims 1-38 or a pharmaceutical composition as claimed in claim 39.
44. A method of treating functional abdominal pain, functional idiopathic diarrhea, inflammatory bowel diseases, drug induced pain, bile salt malabsorption, or lactase or other carbohydrate intolerance in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound as claimed in any one of claims 1-38 or a pharmaceutical composition as claimed in claim 39.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263370329P | 2022-08-03 | 2022-08-03 | |
US63/370,329 | 2022-08-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2024030535A2 true WO2024030535A2 (en) | 2024-02-08 |
WO2024030535A3 WO2024030535A3 (en) | 2024-04-11 |
Family
ID=89849731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/029383 WO2024030535A2 (en) | 2022-08-03 | 2023-08-03 | Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024030535A2 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH579083A5 (en) * | 1972-12-29 | 1976-08-31 | Ciba Geigy Ag | |
US8835424B2 (en) * | 2002-03-28 | 2014-09-16 | Wisconsin Alumni Research Foundation | Selective agents for pain suppression |
US20100261711A1 (en) * | 2009-03-20 | 2010-10-14 | Wisys Technology Foundation | Selective anticonvulsant agents and their uses |
US9006233B2 (en) * | 2011-04-28 | 2015-04-14 | Uwm Research Foundation, Inc. | Gabaergic receptor subtype selective ligands and their uses |
-
2023
- 2023-08-03 WO PCT/US2023/029383 patent/WO2024030535A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2024030535A3 (en) | 2024-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10844070B2 (en) | Peripherally restricted GABA positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system | |
ES2578779T3 (en) | Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents | |
CN110709386B (en) | Bicyclic heteroaryl derivatives, their preparation and use | |
ES2340201T3 (en) | CANNABINOID HEXAHYDRO-CYCLOCYPIRAZOL MODULATORS. | |
CA2853285A1 (en) | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | |
BRPI0616404A2 (en) | substituted 3-starch-tetrahydro-indazolyl cannabinoid modulators and use thereof | |
JP2012517471A (en) | Histamine H3 inverse agonists and antagonists and methods of use thereof | |
WO2017157332A1 (en) | Aromatic amide derivative, preparation method therefor, and pharmaceutical applications thereof | |
ES2926918T3 (en) | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing GABA A receptor agonists | |
JP2010521516A (en) | Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome | |
EP4288440A1 (en) | Peripherally restricted gaba positive allosteric modulators | |
AU2014207918A1 (en) | Conjugates and small molecules which interact with the CD16a receptor | |
CN109789144A (en) | Protein kinase modulators | |
WO2024030535A2 (en) | Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system | |
WO2024030543A2 (en) | Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system | |
US20040229867A1 (en) | Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (R) 2,3-benzodiazepine | |
WO2016026372A1 (en) | Thienocycloalkyl or thienoheterocyclic derivatives, preparation method thereof and use thereof in medicine | |
KR101155753B1 (en) | Pharmaceutical composition including quinoline derivative compound | |
US20050288277A1 (en) | Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (S)-2,3-benzodiazepine | |
JP5127697B2 (en) | Tetrahydrothiopyranopyrazole cannabinoid modulator | |
US8741893B2 (en) | 6,7-dihydro-[1,3,4]thiadiazolo-[3,2-a][1,3]diazepin derivatives and pharmaceutical compositions containing the same as hypnotic or anesthetic agent and method for their preparation | |
US20070254899A1 (en) | Soluble salts of thieno[2,3-d]pyrimidine derivatives | |
WO2008050853A1 (en) | Therapeutic agents for irritable bowel syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23850739 Country of ref document: EP Kind code of ref document: A2 |